STOCK TITAN

FF EAI Robotics nine-month net loss widens to $13M

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
10-Q

Rhea-AI Filing Summary

FF EAI Robotics Ecosystem Inc. reported third-quarter results as RoboShare began generating revenue and the company pursued its robotics and embodied AI strategy. RoboShare generated $4,473 of revenue in both the three and nine months ended September 30, 2026. On October 23, 2026, the company completed its acquisition of majority stockholder FFAI’s robotics business for equity securities; the transaction itself provided no cash proceeds.

For the nine months ended September 30, 2026, net loss was $12,992,755, compared with $6,369,407 in 2025, and net cash used in operating activities was $10,104,256, compared with $4,828,985. Cash and cash equivalents were $3,202,670 at September 30, 2026, and remaining digital assets had a fair value of $2.

Management expects continued losses and negative operating cash flow and said its plans do not alleviate substantial doubt about the company’s ability to continue as a going concern for the one-year period following issuance of the statements. The company’s private placement for up to $10.0 million had not closed as of that date. Its equity purchase facility provides for purchases of up to $50.0 million, subject to contractual conditions; the undrawn commitment is not cash available to fund operations.

0 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 3 points

How the balance works

Positive

  • None.

Negative

  • Major pointGoing-concern doubt remains for the one-year period following issuance of the statements.
  • Moderate pointNine-month net loss rose to $12,992,755 from $6,369,407.
  • Moderate pointNine-month operating cash use rose to $10,104,256 from $4,828,985.

Filing Explained

The 10-Q reports 4,031,975 shares delivered to GKA for possible equity-line purchases were issued and outstanding at September 30, 2026, increasing total shares and diluting holders absent offsets, though no purchase or consideration had occurred. The company may recall them without payment and excludes them from weighted-average shares; on November 16, 2026, GKA held 3,712,269 shares pending purchase.

Third-quarter revenue $4,473 Three months ended September 30, 2026
Third-quarter net loss $2,726,134 Three months ended September 30, 2026; $2,037,819 in 2025
Nine-month net loss $12,992,755 Nine months ended September 30, 2026; $6,369,407 in 2025
Operating cash used $10,104,256 Nine months ended September 30, 2026; $4,828,985 in 2025
Cash and cash equivalents $3,202,670 As of September 30, 2026
Digital assets $2 Fair value as of September 30, 2026
Private placement gross proceeds Up to $10.0 million Private placement had not closed as of the date the statements were issued
Equity purchase facility Up to $50.0 million Purchases are subject to contractual conditions; undrawn commitment is not cash available to fund operations
going concern financial
"substantial doubt about the Company’s ability to continue as a going concern"
Going concern is the accounting assumption that a company will keep operating and meeting its obligations for the foreseeable future. The phrase matters most when a company or its auditors disclose substantial doubt about it, a formal warning that the business may not have enough resources to continue without raising money, restructuring, or selling assets. That language in a filing or press release signals elevated financial risk.
equity line of credit financial
"the Company’s equity line of credit (the “ELOC”) facility"
An equity line of credit is a loan that allows homeowners to borrow money against the value of their property, similar to having a flexible credit card secured by their home. It matters to investors because it provides a way for property owners to access cash for various needs, which can influence real estate markets and overall economic activity. This type of credit offers ongoing borrowing capacity, making it a valuable financial tool for those with significant property equity.
contract liabilities financial
"recorded as contract liabilities and recognized as revenue"
Contract liabilities are amounts a company has been paid in advance for goods or services it still owes to customers — think of them like gift cards or prepaid subscriptions the company must fulfill later. For investors, they show promised future work or deliveries that will turn into revenue over time, reveal cash already collected, and help assess whether a firm has a backlog of obligations that could affect future earnings and cash flow.
Level 3 measurements technical
"lowest priority to valuations based upon unobservable inputs"
current expected credit loss financial
"current expected credit loss (“CECL”) model"
An accounting approach that requires lenders and companies to estimate and record the credit losses they expect on loans and receivables now, using current conditions and reasonable forecasts rather than waiting for a default to occur. It matters to investors because it changes reported reserves and profits up front and gives an earlier, more forward-looking signal of credit quality—like packing an umbrella today because the forecast predicts rain, which affects a company’s cushion against bad loans.
performance obligation financial
"The Company’s performance obligation is to arrange and facilitate"
A performance obligation is a specific promise in a contract to deliver a good or provide a service to a customer, and it is the unit companies use to decide when and how much revenue to record. Think of it like checklist items in a service agreement: each item completed can trigger part of the payment to be recognized as revenue. Investors care because how obligations are identified and satisfied changes the timing and amount of reported revenue and profits, affecting comparisons and valuation.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What revenue did FFR report for the third quarter of 2026?

RoboShare generated $4,473 of revenue for the three months ended September 30, 2026. It also generated $4,473 for the nine months ended that date.

Did FFR close its $10 million PIPE?

No. As of the date the financial statements were issued, the private placement had not closed. It provides for gross proceeds of up to $10.0 million, has no minimum aggregate funding condition, and is intended to fund development and operations of the robotics business.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false --12-31 Q3 0001460702 0001460702 2026-01-01 2026-09-30 0001460702 2026-11-16 0001460702 2026-09-30 0001460702 2025-12-31 0001460702 us-gaap:RelatedPartyMember 2026-09-30 0001460702 us-gaap:RelatedPartyMember 2025-12-31 0001460702 FFR:SeriesA2PreferredStockMember 2026-09-30 0001460702 FFR:SeriesA2PreferredStockMember 2025-12-31 0001460702 us-gaap:SeriesBPreferredStockMember 2026-09-30 0001460702 us-gaap:SeriesBPreferredStockMember 2025-12-31 0001460702 2026-07-01 2026-09-30 0001460702 2025-07-01 2025-09-30 0001460702 2025-01-01 2025-09-30 0001460702 us-gaap:PreferredStockMember FFR:SeriesA2ConvertiblePreferredStockMember 2025-12-31 0001460702 us-gaap:PreferredStockMember FFR:SeriesBConvertiblePreferredStockMember 2025-12-31 0001460702 us-gaap:CommonStockMember 2025-12-31 0001460702 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001460702 us-gaap:ParentMember 2025-12-31 0001460702 us-gaap:RetainedEarningsMember 2025-12-31 0001460702 us-gaap:PreferredStockMember FFR:SeriesA2ConvertiblePreferredStockMember 2026-03-31 0001460702 us-gaap:PreferredStockMember FFR:SeriesBConvertiblePreferredStockMember 2026-03-31 0001460702 us-gaap:CommonStockMember 2026-03-31 0001460702 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0001460702 us-gaap:ParentMember 2026-03-31 0001460702 us-gaap:RetainedEarningsMember 2026-03-31 0001460702 2026-03-31 0001460702 us-gaap:PreferredStockMember FFR:SeriesA2ConvertiblePreferredStockMember 2026-06-30 0001460702 us-gaap:PreferredStockMember FFR:SeriesBConvertiblePreferredStockMember 2026-06-30 0001460702 us-gaap:CommonStockMember 2026-06-30 0001460702 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0001460702 us-gaap:ParentMember 2026-06-30 0001460702 us-gaap:RetainedEarningsMember 2026-06-30 0001460702 2026-06-30 0001460702 us-gaap:PreferredStockMember FFR:SeriesA2ConvertiblePreferredStockMember 2024-12-31 0001460702 us-gaap:PreferredStockMember FFR:SeriesA3ConvertiblePreferredStockMember 2024-12-31 0001460702 us-gaap:PreferredStockMember FFR:SeriesBConvertiblePreferredStockMember 2024-12-31 0001460702 us-gaap:CommonStockMember 2024-12-31 0001460702 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001460702 us-gaap:RetainedEarningsMember 2024-12-31 0001460702 2024-12-31 0001460702 us-gaap:PreferredStockMember FFR:SeriesA2ConvertiblePreferredStockMember 2025-03-31 0001460702 us-gaap:PreferredStockMember FFR:SeriesA3ConvertiblePreferredStockMember 2025-03-31 0001460702 us-gaap:PreferredStockMember FFR:SeriesBConvertiblePreferredStockMember 2025-03-31 0001460702 us-gaap:CommonStockMember 2025-03-31 0001460702 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001460702 us-gaap:RetainedEarningsMember 2025-03-31 0001460702 2025-03-31 0001460702 us-gaap:PreferredStockMember FFR:SeriesA2ConvertiblePreferredStockMember 2025-06-30 0001460702 us-gaap:PreferredStockMember FFR:SeriesA3ConvertiblePreferredStockMember 2025-06-30 0001460702 us-gaap:PreferredStockMember FFR:SeriesBConvertiblePreferredStockMember 2025-06-30 0001460702 us-gaap:CommonStockMember 2025-06-30 0001460702 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001460702 us-gaap:RetainedEarningsMember 2025-06-30 0001460702 2025-06-30 0001460702 us-gaap:PreferredStockMember FFR:SeriesA2ConvertiblePreferredStockMember 2026-01-01 2026-03-31 0001460702 us-gaap:PreferredStockMember FFR:SeriesBConvertiblePreferredStockMember 2026-01-01 2026-03-31 0001460702 us-gaap:CommonStockMember 2026-01-01 2026-03-31 0001460702 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0001460702 us-gaap:ParentMember 2026-01-01 2026-03-31 0001460702 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0001460702 2026-01-01 2026-03-31 0001460702 us-gaap:PreferredStockMember FFR:SeriesA2ConvertiblePreferredStockMember 2026-04-01 2026-06-30 0001460702 us-gaap:PreferredStockMember FFR:SeriesBConvertiblePreferredStockMember 2026-04-01 2026-06-30 0001460702 us-gaap:CommonStockMember 2026-04-01 2026-06-30 0001460702 us-gaap:AdditionalPaidInCapitalMember 2026-04-01 2026-06-30 0001460702 us-gaap:ParentMember 2026-04-01 2026-06-30 0001460702 us-gaap:RetainedEarningsMember 2026-04-01 2026-06-30 0001460702 2026-04-01 2026-06-30 0001460702 us-gaap:PreferredStockMember FFR:SeriesA2ConvertiblePreferredStockMember 2026-07-01 2026-09-30 0001460702 us-gaap:PreferredStockMember FFR:SeriesBConvertiblePreferredStockMember 2026-07-01 2026-09-30 0001460702 us-gaap:CommonStockMember 2026-07-01 2026-09-30 0001460702 us-gaap:AdditionalPaidInCapitalMember 2026-07-01 2026-09-30 0001460702 us-gaap:ParentMember 2026-07-01 2026-09-30 0001460702 us-gaap:RetainedEarningsMember 2026-07-01 2026-09-30 0001460702 us-gaap:PreferredStockMember FFR:SeriesA2ConvertiblePreferredStockMember 2025-01-01 2025-03-31 0001460702 us-gaap:PreferredStockMember FFR:SeriesA3ConvertiblePreferredStockMember 2025-01-01 2025-03-31 0001460702 us-gaap:PreferredStockMember FFR:SeriesBConvertiblePreferredStockMember 2025-01-01 2025-03-31 0001460702 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001460702 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001460702 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001460702 2025-01-01 2025-03-31 0001460702 us-gaap:PreferredStockMember FFR:SeriesA2ConvertiblePreferredStockMember 2025-04-01 2025-06-30 0001460702 us-gaap:PreferredStockMember FFR:SeriesA3ConvertiblePreferredStockMember 2025-04-01 2025-06-30 0001460702 us-gaap:PreferredStockMember FFR:SeriesBConvertiblePreferredStockMember 2025-04-01 2025-06-30 0001460702 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0001460702 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0001460702 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0001460702 2025-04-01 2025-06-30 0001460702 us-gaap:PreferredStockMember FFR:SeriesA2ConvertiblePreferredStockMember 2025-07-01 2025-09-30 0001460702 us-gaap:PreferredStockMember FFR:SeriesA3ConvertiblePreferredStockMember 2025-07-01 2025-09-30 0001460702 us-gaap:PreferredStockMember FFR:SeriesBConvertiblePreferredStockMember 2025-07-01 2025-09-30 0001460702 us-gaap:CommonStockMember 2025-07-01 2025-09-30 0001460702 us-gaap:AdditionalPaidInCapitalMember 2025-07-01 2025-09-30 0001460702 us-gaap:RetainedEarningsMember 2025-07-01 2025-09-30 0001460702 us-gaap:PreferredStockMember FFR:SeriesA2ConvertiblePreferredStockMember 2026-09-30 0001460702 us-gaap:PreferredStockMember FFR:SeriesBConvertiblePreferredStockMember 2026-09-30 0001460702 us-gaap:CommonStockMember 2026-09-30 0001460702 us-gaap:AdditionalPaidInCapitalMember 2026-09-30 0001460702 us-gaap:ParentMember 2026-09-30 0001460702 us-gaap:RetainedEarningsMember 2026-09-30 0001460702 us-gaap:PreferredStockMember FFR:SeriesA2ConvertiblePreferredStockMember 2025-09-30 0001460702 us-gaap:PreferredStockMember FFR:SeriesA3ConvertiblePreferredStockMember 2025-09-30 0001460702 us-gaap:PreferredStockMember FFR:SeriesBConvertiblePreferredStockMember 2025-09-30 0001460702 us-gaap:CommonStockMember 2025-09-30 0001460702 us-gaap:AdditionalPaidInCapitalMember 2025-09-30 0001460702 us-gaap:RetainedEarningsMember 2025-09-30 0001460702 2025-09-30 0001460702 FFR:NanoSynexLtdMember 2022-12-31 0001460702 FFR:SubscriptionAgreementMember 2025-09-01 2025-09-30 0001460702 FFR:SeriesBConvertiblePreferredStockMember FFR:SubscriptionAgreementMember 2025-09-30 0001460702 FFR:SeriesBConvertiblePreferredStockMember FFR:SubscriptionAgreementMember 2025-09-01 2025-09-30 0001460702 2025-01-01 2025-12-31 0001460702 us-gaap:SubsequentEventMember 2026-10-12 2026-10-12 0001460702 us-gaap:FairValueInputsLevel1Member 2026-09-30 0001460702 us-gaap:FairValueInputsLevel2Member 2026-09-30 0001460702 us-gaap:FairValueInputsLevel3Member 2026-09-30 0001460702 us-gaap:FairValueInputsLevel1Member 2025-12-31 0001460702 us-gaap:FairValueInputsLevel2Member 2025-12-31 0001460702 us-gaap:FairValueInputsLevel3Member 2025-12-31 0001460702 FFR:MarizymeNotesMember 2025-01-01 2025-12-31 0001460702 FFR:MarizymeNotesMember 2026-05-12 2026-05-12 0001460702 FFR:MarizymeNotesMember 2026-01-01 2026-09-30 0001460702 2026-02-01 2026-02-28 0001460702 us-gaap:WarrantMember 2024-11-20 0001460702 FFR:PreFundedWarrantsMember 2024-11-20 0001460702 FFR:PreFundedWarrantsMember 2026-09-30 0001460702 FFR:CommonStockWarrantsMember 2025-12-31 0001460702 FFR:CommonStockWarrantsMember srt:MinimumMember 2025-12-31 0001460702 FFR:CommonStockWarrantsMember srt:MaximumMember 2025-12-31 0001460702 FFR:CommonStockWarrantsMember 2025-01-01 2025-12-31 0001460702 FFR:CommonStockWarrantsMember 2026-01-01 2026-09-30 0001460702 FFR:CommonStockWarrantsMember 2026-09-30 0001460702 FFR:CommonStockWarrantsMember srt:MinimumMember 2026-09-30 0001460702 FFR:CommonStockWarrantsMember srt:MaximumMember 2026-09-30 0001460702 FFR:CommonStockWarrantsMember 2024-12-31 0001460702 FFR:CommonStockWarrantsMember srt:MinimumMember 2024-12-31 0001460702 FFR:CommonStockWarrantsMember srt:MaximumMember 2024-12-31 0001460702 FFR:CommonStockWarrantsMember 2024-01-01 2024-12-31 0001460702 FFR:CommonStockWarrantsMember 2025-01-01 2025-09-30 0001460702 FFR:CommonStockWarrantsMember srt:MinimumMember 2025-01-01 2025-09-30 0001460702 FFR:CommonStockWarrantsMember srt:MaximumMember 2025-01-01 2025-09-30 0001460702 FFR:CommonStockWarrantsMember 2025-09-30 0001460702 FFR:CommonStockWarrantsMember srt:MinimumMember 2025-09-30 0001460702 FFR:CommonStockWarrantsMember srt:MaximumMember 2025-09-30 0001460702 FFR:PreFundedWarrantsMember 2025-09-30 0001460702 us-gaap:FairValueInputsLevel1Member 2026-01-01 2026-09-30 0001460702 us-gaap:FairValueInputsLevel2Member 2026-01-01 2026-09-30 0001460702 us-gaap:FairValueInputsLevel3Member 2026-01-01 2026-09-30 0001460702 us-gaap:FairValueInputsLevel1Member 2024-12-31 0001460702 us-gaap:FairValueInputsLevel2Member 2024-12-31 0001460702 us-gaap:FairValueInputsLevel3Member 2024-12-31 0001460702 us-gaap:FairValueInputsLevel1Member 2025-01-01 2025-12-31 0001460702 us-gaap:FairValueInputsLevel2Member 2025-01-01 2025-12-31 0001460702 us-gaap:FairValueInputsLevel3Member 2025-01-01 2025-12-31 0001460702 us-gaap:MeasurementInputRiskFreeInterestRateMember 2026-09-30 0001460702 us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MinimumMember 2025-09-30 0001460702 us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MaximumMember 2025-09-30 0001460702 us-gaap:MeasurementInputPriceVolatilityMember 2026-09-30 0001460702 us-gaap:MeasurementInputPriceVolatilityMember srt:MinimumMember 2025-09-30 0001460702 us-gaap:MeasurementInputPriceVolatilityMember srt:MaximumMember 2025-09-30 0001460702 us-gaap:MeasurementInputExpectedTermMember 2026-09-30 0001460702 us-gaap:MeasurementInputExpectedTermMember srt:MinimumMember 2025-09-30 0001460702 us-gaap:MeasurementInputExpectedTermMember srt:MaximumMember 2025-09-30 0001460702 us-gaap:MeasurementInputExpectedDividendRateMember 2026-09-30 0001460702 us-gaap:MeasurementInputExpectedDividendRateMember 2025-09-30 0001460702 FFR:TwoThounsandTwentyFiveConvertibleNoteMember 2025-04-28 0001460702 FFR:TwoThounsandTwentyFiveConvertibleNoteMember 2025-04-28 2025-04-28 0001460702 FFR:TwoThounsandTwentyFiveConvertibleNoteMember 2025-06-04 0001460702 FFR:TwoThounsandTwentyFiveConvertibleNoteMember 2026-01-28 0001460702 FFR:TwoThounsandTwentyFiveConvertibleNoteMember 2025-01-01 2025-12-31 0001460702 FFR:SharesPurchaseAgreementMember us-gaap:CommonStockMember FFR:GoldKingArthurHoldingLimitedMember 2026-09-14 2026-09-14 0001460702 FFR:SharesPurchaseAgreementMember us-gaap:CommonStockMember 2026-01-01 2026-09-30 0001460702 us-gaap:EmployeeStockOptionMember 2026-01-01 2026-09-30 0001460702 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-09-30 0001460702 us-gaap:WarrantMember 2026-01-01 2026-09-30 0001460702 us-gaap:WarrantMember 2025-01-01 2025-09-30 0001460702 us-gaap:PreferredStockMember 2026-01-01 2026-09-30 0001460702 us-gaap:PreferredStockMember 2025-01-01 2025-09-30 0001460702 us-gaap:ConvertibleDebtMember 2026-01-01 2026-09-30 0001460702 us-gaap:ConvertibleDebtMember 2025-01-01 2025-09-30 0001460702 FFR:ConsultingAgreementMember FFR:AibotUSOperationIncMember 2026-07-29 2026-07-29 0001460702 FFR:ConsultingAgreementMember FFR:AibotUSOperationIncMember 2026-07-01 2026-09-30 0001460702 FFR:AibotUSOperationIncMember FFR:ConsultingAgreementMember 2026-09-30 0001460702 FFR:UpfrontPaymentMember FFR:LicenseAgreementMember 2022-01-13 2022-01-13 0001460702 FFR:LicenseAgreementMember 2022-01-13 2022-01-13 0001460702 FFR:LicenseAgreementMember 2026-01-01 2026-09-30 0001460702 FFR:LicenseAgreementMember 2025-01-01 2025-09-30 0001460702 FFR:CoDevelopmentAgreementMember 2024-04-11 2024-04-11 0001460702 FFR:CoDevelopmentAgreementMember 2024-04-11 0001460702 FFR:CoDevelopmentAgreementMember 2024-04-12 0001460702 FFR:FaradaySubscriptionAgreementMember us-gaap:InvestorMember 2025-09-29 2025-09-29 0001460702 FFR:FaradaySubscriptionAgreementMember FFR:LegalFirmMember 2025-09-29 2025-09-29 0001460702 FFR:FaradaySubscriptionAgreementMember 2025-09-29 0001460702 FFR:FaradaySubscriptionAgreementMember 2025-09-29 2025-09-29 0001460702 FFR:FaradaySubscriptionAgreementMember FFR:AdvisorMember 2025-09-29 2025-09-29 0001460702 FFR:FaradaySubscriptionAgreementMember 2026-09-30 0001460702 us-gaap:CommonStockMember FFR:CommonStockPurchaseAgreementMember srt:MaximumMember 2024-11-19 2024-11-19 0001460702 FFR:SeriesA2ConvertiblePreferredStockMember 2026-09-30 0001460702 FFR:SeriesA3ConvertiblePreferredStockMember 2026-09-30 0001460702 FFR:SeriesBConvertiblePreferredStockMember 2026-09-30 0001460702 FFR:SeriesBConvertiblePreferredStockMember 2025-09-29 2025-09-29 0001460702 FFR:SeriesBConvertiblePreferredStockMember 2025-09-29 0001460702 FFR:SeriesA3ConvertiblePreferredStockMember 2025-07-28 2025-07-28 0001460702 FFR:SeriesA3ConvertiblePreferredStockMember 2025-07-28 0001460702 FFR:SeriesA2ConvertiblePreferredStockMember 2024-11-20 2024-11-20 0001460702 FFR:SeriesA2ConvertiblePreferredStockMember 2024-11-20 0001460702 FFR:SeriesA2ConvertiblePreferredStockMember FFR:YiHuaChenMember 2024-11-18 2024-11-18 0001460702 FFR:SeriesA2ConvertiblePreferredStockMember 2025-12-31 0001460702 FFR:SeriesA3ConvertiblePreferredStockMember 2025-12-31 0001460702 us-gaap:CommonStockMember 2025-01-01 2025-12-31 0001460702 us-gaap:CommonStockMember srt:MaximumMember 2025-12-31 0001460702 us-gaap:CommonStockMember srt:MinimumMember 2025-12-31 0001460702 FFR:SeriesBConvertiblePreferredStockMember 2026-01-01 2026-09-30 0001460702 FFR:SeriesA3ConvertiblePreferredStockMember 2024-11-20 0001460702 FFR:SeriesBConvertiblePreferredStockMember 2024-11-20 0001460702 FFR:SharesPurchaseAgreementMember us-gaap:CommonStockMember FFR:GoldKingArthurHoldingLimitedMember 2026-06-16 2026-06-16 0001460702 FFR:SharesPurchaseAgreementMember FFR:GoldKingArthurHoldingLimitedMember 2026-06-16 2026-06-16 0001460702 FFR:SharesPurchaseAgreementMember us-gaap:CommonStockMember FFR:GoldKingArthurHoldingLimitedMember 2026-07-28 2026-07-28 0001460702 FFR:SharesPurchaseAgreementMember us-gaap:CommonStockMember 2026-07-01 2026-09-30 0001460702 FFR:SharesPurchaseAgreementMember 2026-01-01 2026-09-30 0001460702 FFR:SharesPurchaseAgreementMember us-gaap:SubsequentEventMember 2026-10-01 2026-10-01 0001460702 FFR:SharesPurchaseAgreementMember 2026-09-30 0001460702 us-gaap:EmployeeStockOptionMember FFR:TwoThousandTwentyFiveStockIncentivePlanMember 2026-09-30 0001460702 us-gaap:WarrantMember 2026-09-30 0001460702 FFR:CompensatoryWarrantActivityMember 2026-09-30 0001460702 FFR:CompensatoryWarrantActivityMember 2025-09-30 0001460702 FFR:NoncompensatoryEquityClassifiedWarrantsMember FFR:TwoThousandTwentyTwoAlphaMember 2022-12-22 0001460702 FFR:NoncompensatoryEquityClassifiedWarrantsMember FFR:TwoThousandTwentyTwoAlphaMember 2023-12-05 0001460702 FFR:NoncompensatoryEquityClassifiedWarrantsMember FFR:TwoThousandTwentyTwoAlphaMember 2024-01-01 2024-12-31 0001460702 FFR:NoncompensatoryEquityClassifiedWarrantsMember FFR:TwoThousandTwentyTwoAlphaMember 2026-09-30 0001460702 FFR:TwoThousandTwentyTwoAlphaMember FFR:NoncompensatoryEquityClassifiedWarrantsMember 2024-02-26 0001460702 FFR:TwoThousandTwentyTwoAlphaMember FFR:NoncompensatoryEquityClassifiedWarrantsMember 2024-02-27 0001460702 FFR:TwoThousandTwentyTwoAlphaMember 2024-02-27 2024-02-27 0001460702 FFR:AlphaCapitalMember FFR:NoncompensatoryEquityClassifiedWarrantsMember 2024-09-05 0001460702 FFR:AlphaCapitalMember FFR:NoncompensatoryEquityClassifiedWarrantsMember 2024-09-06 0001460702 FFR:AlphaCapitalMember 2024-09-06 2024-09-06 0001460702 FFR:SecuritiesPurchaseAgreementMember FFR:YiHuaChenMember 2024-04-12 0001460702 FFR:AlphaCapitalMember FFR:NoncompensatoryEquityClassifiedWarrantsMember 2024-02-27 0001460702 FFR:AlphaCapitalMember 2024-09-09 0001460702 FFR:AlphaCapitalMember 2024-09-09 2024-09-09 0001460702 FFR:PreFundedWarrantsMember 2024-09-06 0001460702 FFR:PreFundedWarrantsMember 2024-01-01 2024-12-31 0001460702 FFR:PreFundedWarrantsMember 2026-09-30 0001460702 us-gaap:WarrantMember 2024-09-06 2024-09-06 0001460702 FFR:CompensatoryWarrantActivityMember 2024-11-20 0001460702 FFR:CompensatoryWarrantActivityMember 2024-11-20 2024-11-20 0001460702 us-gaap:ConvertibleDebtMember 2025-04-28 0001460702 us-gaap:ConvertibleDebtMember 2025-04-27 0001460702 us-gaap:ConvertibleDebtMember 2025-04-28 2025-04-28 0001460702 FFR:PlacementAgentWarrantsMember 2025-09-29 0001460702 FFR:PlacementAgentWarrantsMember 2026-09-30 0001460702 FFR:CompensatoryWarrantActivityMember 2026-01-01 2026-09-30 0001460702 FFR:NonCompensatoryWarrantActivityMember 2026-01-01 2026-09-30 0001460702 FFR:SeriesA2ConvertiblePreferredStockMember 2026-09-30 0001460702 FFR:SeriesBConvertiblePreferredStockMember 2026-09-30 0001460702 us-gaap:WarrantMember 2026-09-30 0001460702 FFR:CompensatoryWarrantActivityMember 2025-12-31 0001460702 FFR:CompensatoryWarrantActivityMember srt:MinimumMember 2025-12-31 0001460702 FFR:CompensatoryWarrantActivityMember srt:MaximumMember 2025-12-31 0001460702 FFR:CompensatoryWarrantActivityMember 2025-01-01 2025-12-31 0001460702 FFR:CompensatoryWarrantActivityMember srt:MinimumMember 2026-09-30 0001460702 FFR:CompensatoryWarrantActivityMember srt:MaximumMember 2026-09-30 0001460702 FFR:CompensatoryWarrantActivityMember 2024-12-31 0001460702 FFR:CompensatoryWarrantActivityMember srt:MinimumMember 2024-12-31 0001460702 FFR:CompensatoryWarrantActivityMember srt:MaximumMember 2024-12-31 0001460702 FFR:CompensatoryWarrantActivityMember 2024-01-01 2024-12-31 0001460702 FFR:CompensatoryWarrantActivityMember 2025-01-01 2025-09-30 0001460702 FFR:CompensatoryWarrantActivityMember srt:MinimumMember 2025-01-01 2025-09-30 0001460702 FFR:CompensatoryWarrantActivityMember srt:MaximumMember 2025-01-01 2025-09-30 0001460702 FFR:CompensatoryWarrantActivityMember srt:MinimumMember 2025-09-30 0001460702 FFR:CompensatoryWarrantActivityMember srt:MaximumMember 2025-09-30 0001460702 FFR:NonCompensatoryWarrantActivityMember 2025-12-31 0001460702 FFR:NonCompensatoryWarrantActivityMember srt:MinimumMember 2025-12-31 0001460702 FFR:NonCompensatoryWarrantActivityMember srt:MaximumMember 2025-12-31 0001460702 FFR:NonCompensatoryWarrantActivityMember 2025-01-01 2025-12-31 0001460702 FFR:NonCompensatoryWarrantActivityMember 2026-01-01 2026-09-30 0001460702 FFR:NonCompensatoryWarrantActivityMember 2026-09-30 0001460702 FFR:NonCompensatoryWarrantActivityMember srt:MinimumMember 2026-09-30 0001460702 FFR:NonCompensatoryWarrantActivityMember srt:MaximumMember 2026-09-30 0001460702 FFR:NonCompensatoryWarrantActivityMember 2024-12-31 0001460702 FFR:NonCompensatoryWarrantActivityMember srt:MinimumMember 2024-12-31 0001460702 FFR:NonCompensatoryWarrantActivityMember srt:MaximumMember 2024-12-31 0001460702 FFR:NonCompensatoryWarrantActivityMember 2024-01-01 2024-12-31 0001460702 FFR:NonCompensatoryWarrantActivityMember 2025-01-01 2025-09-30 0001460702 FFR:NonCompensatoryWarrantActivityMember srt:MinimumMember 2025-09-30 0001460702 FFR:NonCompensatoryWarrantActivityMember srt:MaximumMember 2025-09-30 0001460702 FFR:NonCompensatoryWarrantActivityMember 2025-09-30 0001460702 2026-01-01 2026-01-31 0001460702 2026-04-15 0001460702 2026-04-15 2026-04-15 0001460702 us-gaap:PrivatePlacementMember 2026-09-30 0001460702 FFR:LeadInvestorAgreementMember us-gaap:ExecutiveCommitteeMember 2026-01-01 2026-09-30 0001460702 FFR:LeadInvestorAgreementMember srt:ChiefExecutiveOfficerMember 2026-01-01 2026-09-30 0001460702 FFR:LeadInvestorAgreementMember srt:BoardOfDirectorsChairmanMember 2026-01-01 2026-09-30 0001460702 FFR:TransitionServicesAgreementMember 2026-01-01 2026-09-30 0001460702 FFR:TransitionServicesAgreementMember 2026-09-30 0001460702 FFR:TransitionServicesAgreementMember us-gaap:RelatedPartyMember 2025-12-31 0001460702 FFR:FaradayFutureIntelligentElectricIncMember 2026-07-19 2026-07-19 0001460702 FFR:FaradayFutureIntelligentElectricIncMember 2026-07-30 2026-07-30 0001460702 srt:DirectorMember FFR:FaradayFutureIntelligentElectricIncMember 2026-07-19 2026-07-19 0001460702 FFR:FaradayFutureIntelligentElectricIncMember 2026-07-19 0001460702 FFR:FaradayFutureIntelligentElectricIncMember 2026-01-01 2026-09-30 0001460702 FFR:FaradayFutureIntelligentElectricIncMember 2026-09-30 0001460702 FFR:ConsultingAgreementMember 2026-07-29 2026-07-29 0001460702 FFR:ConsultingAgreementMember 2026-07-01 2026-09-30 0001460702 FFR:ConsultingAgreementMember 2026-01-01 2026-09-30 0001460702 FFR:AdvisoryAgreementMember 2025-10-02 2025-10-02 0001460702 FFR:AdvisoryAgreementMember 2026-07-01 2026-09-30 0001460702 FFR:AdvisoryAgreementMember 2026-01-01 2026-09-30 0001460702 FFR:AdvisoryAgreementMember FFR:YuetingJiaMember 2026-09-30 0001460702 FFR:ConsultingServicesAgreementMember FFR:FFGlobalPartnersLlcMember 2026-01-28 2026-01-28 0001460702 FFR:ConsultingServicesAgreementMember FFR:FFGlobalPartnersLlcMember 2026-07-01 2026-09-30 0001460702 FFR:ConsultingServicesAgreementMember FFR:FFGlobalPartnersLlcMember 2026-01-01 2026-09-30 0001460702 FFR:ConsultingServicesAgreementMember FFR:FFGlobalPartnersLlcMember 2026-09-30 0001460702 FFR:RoboticsAcquisitionMember 2026-09-25 2026-09-25 0001460702 us-gaap:CommonStockMember us-gaap:SubsequentEventMember FFR:DefinitiveTransactionAgreementMember FFR:FFEAIRoboticsIncMember 2026-10-23 2026-10-23 0001460702 FFR:SeriesCNonVotingConvertiblePreferredStockMember us-gaap:SubsequentEventMember FFR:DefinitiveTransactionAgreementMember FFR:FFEAIRoboticsIncMember 2026-10-23 2026-10-23 0001460702 FFR:FFEAIRoboticsIncMember us-gaap:SubsequentEventMember 2026-10-12 2026-10-12 0001460702 FFR:FFEAIRoboticsIncMember us-gaap:SubsequentEventMember 2026-10-12 0001460702 us-gaap:WarrantMember 2025-01-01 2025-12-31 0001460702 us-gaap:WarrantMember 2024-01-01 2024-12-31 0001460702 FFR:TwoThousandTwentyTwoAlphaDebentureMember FFR:NoncompensatoryEquityClassifiedWarrantsMember 2022-12-22 0001460702 FFR:TwoThousandTwentyTwoAlphaDebentureMember FFR:NoncompensatoryEquityClassifiedWarrantsMember 2024-01-01 2024-12-31 0001460702 FFR:TwoThousandTwentyTwoAlphaDebentureMember FFR:NoncompensatoryEquityClassifiedWarrantsMember 2024-12-31 0001460702 FFR:TwoThousandTwentyTwoAlphaDebentureMember FFR:AlphaCapitalMember 2024-01-01 2024-12-31 0001460702 FFR:TwoThousandTwentyTwoAlphaDebentureMember 2024-02-27 0001460702 FFR:TwoThousandTwentyTwoAlphaDebentureMember FFR:NoncompensatoryEquityClassifiedWarrantsMember 2024-09-05 0001460702 FFR:TwoThousandTwentyTwoAlphaDebentureMember FFR:NoncompensatoryEquityClassifiedWarrantsMember 2024-09-06 0001460702 FFR:TwoThousandTwentyTwoAlphaDebentureMember 2024-09-06 2024-09-06 0001460702 FFR:TwoThousandTwentyTwoAlphaDebentureMember 2025-04-27 0001460702 FFR:TwoThousandTwentyTwoAlphaDebentureMember 2025-04-28 0001460702 FFR:TwoThousandTwentyTwoAlphaDebentureMember 2024-09-09 0001460702 FFR:TwoThousandTwentyTwoAlphaDebentureMember 2024-09-09 2024-09-09 0001460702 FFR:TwoThousandTwentyTwoAlphaCapitalMember FFR:NoncompensatoryEquityClassifiedWarrantsMember 2026-09-30 0001460702 FFR:TwoThousandTwentyFourAlphaCapitalMember FFR:NoncompensatoryEquityClassifiedWarrantsMember 2026-09-30 0001460702 FFR:SecuritiesPurchaseAgreementMember 2024-04-12 2024-04-12 0001460702 FFR:SecuritiesPurchaseAgreementMember 2024-10-25 2024-10-25 0001460702 FFR:SegmentReportingExpenseInformationMember 2026-07-01 2026-09-30 0001460702 FFR:SegmentReportingExpenseInformationMember 2025-07-01 2025-09-30 0001460702 FFR:SegmentReportingExpenseInformationMember 2026-01-01 2026-09-30 0001460702 FFR:SegmentReportingExpenseInformationMember 2025-01-01 2025-09-30 0001460702 us-gaap:SubsequentEventMember 2026-10-01 0001460702 us-gaap:SubsequentEventMember us-gaap:CommonStockMember 2026-10-01 2026-10-01 0001460702 us-gaap:SubsequentEventMember 2026-10-01 2026-10-01 0001460702 us-gaap:SubsequentEventMember FFR:DefinitiveTransactionAgreementMember 2026-10-23 2026-10-23 0001460702 us-gaap:ConvertiblePreferredStockMember us-gaap:SubsequentEventMember 2026-10-12 2026-10-12 0001460702 FFR:SecuritiesPurchaseAgreementMember us-gaap:SubsequentEventMember 2026-10-12 2026-10-12 0001460702 FFR:SecuritiesPurchaseAgreementMember us-gaap:SubsequentEventMember us-gaap:CommonStockMember 2026-10-12 0001460702 us-gaap:SubsequentEventMember FFR:OneInvestorMember 2026-10-12 2026-10-12 0001460702 us-gaap:SubsequentEventMember 2026-10-31 0001460702 us-gaap:SubsequentEventMember us-gaap:CommonStockMember 2026-11-12 2026-11-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure FFR:Segment

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2026

 

or

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _____________ to _____________

 

Commission File Number: 001-37428

 

FF EAI Robotics Ecosystem Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   26-3474527

(State or other jurisdiction

of incorporation or organization)

 

(I.R.S. Employer

Identification No.)

 

1990 E. Grand Ave., El Segundo, CA   90245
(Address of principal executive offices)   (Zip Code)

 

(310) 853-1683

(Registrant’s telephone number, including area code)

 

AIxCrypto Holdings, Inc.

(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol   Name of each exchange on which registered
Common Stock, par value $.001 per share   FFR   The Nasdaq Capital Market of The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes ☐ No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☐
Non-accelerated filer ☒ Smaller reporting company ☒
    Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☒ No

 

As of November 16, 2026, there were 27,674,296 shares of the registrant’s common stock, par value $0.001 per share, issued (including 3,712,269 shares held by GKA pending purchase under the equity line of credit).

 

 

 

 

 

 

TABLE OF CONTENTS

 

      Page
PART I. Financial Information   3
       
Item 1. Financial Statements   3
Condensed Consolidated Financial Statements (Unaudited)   3
  Condensed Consolidated Balance Sheets (Unaudited)   3
  Condensed Consolidated Statement of Operations (Unaudited)   4
  Condensed Consolidated Statement of Changes in Stockholders’ Equity (Unaudited)   5
  Condensed Consolidated Statements of Cash Flow (Unaudited)   6
  Notes to Unaudited Condensed Consolidated Financial Statements   7
       
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations   30
Item 3. Quantitative and Qualitative Disclosures About Market Risk   40
Item 4. Controls and Procedures   40
       
PART II. Other Information   41
       
Item 1. Legal Proceedings   41
Item 1A. Risk Factors   41
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds   41
Item 3. Defaults Upon Senior Securities   41
Item 4. Mine Safety Disclosures   41
Item 5. Other Information   42
Item 6. Exhibits   43

 

2

 

 

PART I – FINANCIAL INFORMATION

 

ITEM 1. FINANCIAL STATEMENTS

 

FF EAI ROBOTICS ECOSYSTEM INC.

(Formerly known as AIxCrypto Holdings, Inc.)

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

 

   (Unaudited)     
   September 30,   December 31, 
   2026   2025 
ASSETS          
Current assets          
Cash and cash equivalents  $3,202,670   $19,332,707 
Digital assets   2    10,250,497 
Prepaid expenses and other current assets   461,076    1,028,506 
Other receivable - related party    1,866,096    — 
Short-term notes receivable, net of allowance for credit losses of nil at September 30, 2026 and $4.6 million at December 31, 2025   —    343,060 
Other current assets - related party   125,000    — 
Total current assets   5,654,844    30,954,770 
Non-current assets          
Intangible assets   833,181    314,727 
Other assets - related party   380,404    10,349 
Total non-current assets   1,213,585    325,076 
Total Assets  $6,868,429   $31,279,846 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
Current liabilities          
Accounts payable  $1,344,727   $1,259,944 
Related party payable   321,667    1,648,945 
Accrued expenses and other current liabilities   155,984    136,234 
Warrant liabilities   74,623    141,878 
Convertible debt   —    142,236 
Total current liabilities   1,897,001    3,329,237 
Commitments and Contingencies (Note 13)          
Stockholders’ Equity          
Preferred stock Series A-2, $0.001 par value; 7,000 shares authorized; 601 shares issued and outstanding as of September 30, 2026 and December 31, 2025  $659,040   $659,040 
Preferred stock Series B, $0.001 par value; 500,000 shares authorized; 4,122 and 39,943 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively   3,218,106    31,183,357 
Common stock, $0.001 par value; 225,000,000 shares authorized; 26,358,983 and 5,160,383 shares issued as of September 30, 2026 and December 31, 2025, respectively, 22,327,008 and 5,160,383 shares outstanding as of September 30, 2026 and December 31, 2025, respectively*   86,905    69,738 
Additional paid-in capital   166,029,774    136,065,924 
Parent company equity held at cost   (12,002,192)   — 
Accumulated deficit   (153,020,205)   (140,027,450)
Total Stockholders’ Equity   4,971,428    27,950,609 
Total Liabilities & Stockholders’ Equity  $6,868,429   $31,279,846 

 

*As of September 30, 2026, shares of common stock issued exceeded shares of common stock outstanding by 4,031,975 shares, representing shares pre-delivered under the Company’s equity line of credit arrangement. These shares were pending future purchases and remained subject to recall by the Company and, accordingly, were included in shares issued but excluded from shares outstanding. See Note 15 to the condensed consolidated financial statements.

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

3

 

 

FF EAI ROBOTICS ECOSYSTEM INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

 

   2026   2025   2026   2025 
  

For the Three Months Ended

September 30,

  

For the Nine Months Ended

September 30,

 
   2026   2025   2026   2025 
                 
Revenue  $4,473    —   $4,473    — 
Cost of revenue   14,114    —    14,114      
Gross loss   (9,641)   —    (9,641)   — 
                     
EXPENSES                    
General and administrative   4,282,759    1,891,108    10,699,149    5,780,572 
Sales and Marketing   20,000    —    743,937    — 
Research and development   —    105,576    10,146    156,558 
Credit loss expense - short-term note receivable   —    (567,000)   142,574    (99,000)
Total expenses   4,302,759    1,429,684    11,595,806    5,838,130 
                     
LOSS FROM OPERATIONS   (4,312,400)   (1,429,684)   (11,605,447)   (5,838,130)
                     
OTHER EXPENSE (INCOME), NET                    
(Gain) loss on change in fair value of warrant liabilities   7,371    148,346    (67,255)   93,148 
(Gain) loss on change in fair value of convertible debt   —    197,667    (10,236)   159,793 
Loss on settlement of short-term note receivable   —    —    375,844    — 
Impairment of intangible assets   —    —    182,619    — 
Interest expense   —    455,941    —    635,607 
Interest income   (18,162)   (193,819)   (448,135)   (449,249)
Loss on issuance of convertible debt   —    —    —    91,943 
Loss on equity line of credit (“ELOC”) facility   3,915    —    3,915    — 
ELOC commitment fee   100,000    —    100,000    — 
Net (gain) loss on digital assets   (1,679,390)   —    1,250,556    — 
Total other expense (income), net   (1,586,266)   608,135    1,387,308    531,242 
                     
LOSS BEFORE PROVISION FOR INCOME TAXES   (2,726,134)   (2,037,819)   (12,992,755)   (6,369,372)
                     
PROVISION FOR INCOME TAXES   —    —    —    35 
                     
NET LOSS   (2,726,134)   (2,037,819)   (12,992,755)   (6,369,407)
                     
Deemed dividend arising from warrant down-round provision   —   $(867,796)   —   $(869,382)
                     
Net loss attributable to common stockholders  $(2,726,134)  $(2,905,615)  $(12,992,755)  $(7,238,789)
                     
Total net loss per share of common stock, basic and diluted  $(0.13)  $(4.68)  $(0.80)  $(4.35)
Weighted-average number of shares outstanding, basic and diluted   20,787,933    620,694    16,307,498    1,662,223 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

4

 

 

FF EAI ROBOTICS ECOSYSTEM INC.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

(Unaudited)

 

   Shares   Amount   Shares   Amount   Shares   Amount   Capital   cost   Deficit   Equity 
  

Series A-2

Convertible

Preferred Stock

  

Series B

Convertible

Preferred Stock

   Common Stock   Additional Paid-In  

Parent company

equity held at

   Accumulated  

Total

 Stockholders’

 
   Shares   Amount   Shares   Amount   Shares   Amount   Capital   cost   Deficit   Equity 
Balance at December 31, 2025   601   $659,040    39,943   $31,183,357    5,160,383   $69,738   $136,065,924    —   $(140,027,450)  $27,950,609 
Issuance of common stock for the conversion of Series B preferred shares   -    -    (33,858)   (26,432,819)   15,074,610    15,075    26,417,744    —    —    — 
Net Loss   —    —    —    —    —    —    —    —    (6,079,016)   (6,079,016)
Balance at March 31, 2026   601    659,040    6,085    4,750,538    20,234,993    84,813    162,483,668    —    (146,106,466)   21,871,593 
Parent company equity held at cost   —    —    —    —    —    —    —    (12,002,192)   —    (12,002,192)
Net Loss   —    —    —    —    —    —    —    —    (4,187,605)   (4,187,605)
Balance at June 30, 2026   601    659,040    6,085    4,750,538    20,234,993    84,813    162,483,668    (12,002,192)   (150,294,071)   5,681,796 
Issuance of common stock for the conversion of Series B preferred shares   —    —    (1,963)   (1,532,432)   873,891    874    1,531,558    —    —    — 
Issuance of common stock under ELOC purchases   —    —    —    —    13,000    13    15,247    —    —    15,260 
Issuance of common stock to consultant   —    —    —    —    1,205,124    1,205    1,999,301    —    —    2,000,506 
Net Loss   —    —    —    —    —    —    —    —    (2,726,134)   (2,726,134)
Balance at September 30, 2026   601   $659,040    4,122   $3,218,106    22,327,008   $86,905   $166,029,774   $(12,002,192)  $(153,020,205)  $4,971,428 

 

   Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount   Capital   Deficit   Equity 
   Series A-2   Series A-3   Series B                     
   Convertible   Convertible   Convertible           Additional       Total 
   Preferred Stock   Preferred Stock   Preferred Stock   Common Stock   Paid-In   Accumulated   Stockholders’ 
   Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount   Capital   Deficit   Equity 
Balance at December 31, 2024   6,256   $5,716,400    —    —    —    —    736,431   $65,314   $119,958,897   $(123,061,575)  $2,679,036 
Issuance of common stock for the conversion of Series A-2 preferred shares   (3,235)   (2,893,306)   -     -     -     -     888,879    889    2,892,417    —    — 
Stock-based compensation   —    —         —    —    —    —    —    269    —    269 
Net Loss   —    —    —    —    —    —    —    —    —    (2,646,172)   (2,646,172)
Balance at March 31, 2025   3,021    2,823,094    —    —    —    —    1,625,310    66,203    122,851,583    (125,707,745)   33,134 
Issuance of common stock for the conversion of Series A-2 preferred shares   (37)   (33,087)   -     -     —    —    10,165    10    33,076    —    — 
Net Loss   —    —    —    —    —    —    —    —    —    (1,685,417)   (1,685,417)
Balance at June 30, 2025   2,984    2,790,007    -     -     —    —    1,635,475    66,213    122,884,659    (127,393,162)   (1,652,283)
Issuance of common stock for the conversion of Series A-2 preferred shares   (2,383)   (2,130,967)   —    —    —    —    1,023,658    1,024    2,129,945    —    — 
Issuance of Series A-3 preferred shares upon closing of private placement   —    —    4,500    4,257,937    —    —    —    —    —    —    4,257,937 
Issuance of Series B preferred shares upon closing of private placement   —    —    —    —    39,943    31,183,357    —    —    —    —    31,183,357 
Issuance of common stock and warrants upon closing of private placement   —    —    —    —    —    —    497,689    497    6,795,387    —    6,795,885 
Net loss   —    —    —    —    —    —    —    —    —    (2,037,819)   (2,037,819)
Balance at September 30, 2025   601   $659,040    4,500   $4,257,937    39,943   $31,183,357    3,156,822   $67,734   $131,809,991   $(129,430,981)  $38,547,077 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

5

 

 

FF EAI ROBOTICS ECOSYSTEM INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

 

   2026   2025 
   For the Nine Months ended September 30, 
   2026   2025 
CASH FLOWS FROM OPERATING ACTIVITIES          
Net loss  $(12,992,755)  $(6,369,407)
Adjustments to reconcile loss from operations to net cash used in operating activities:          
Stock-based compensation   —    269 
Change in fair value of warrant liabilities   (67,255)   93,148 
(Gain)/Loss on change in fair value of convertible debt   (10,236)   159,793 
Loss on issuance of convertible debt   —    91,943 
Legal expenses deducted from issuance of convertible debt   —    20,000 
Loss on settlement of short-term note receivable   375,844    — 
Provision for credit losses of short-term note receivable   142,574    (99,000)
Impairment of intangible assets   182,619    — 
Accrued interest income   (293,646)   (428,915)
Amortization of penalty on promissory note   —    635,607 
ELOC commitment fee   100,000    — 
Loss on ELOC facility   3,915    — 
Net loss on digital assets   1,250,556    — 
Other operating activities settled in digital assets   337,839    — 
Amortization of capitalized software   14,114    — 
Issuance of common stock to consultant   2,000,506    325,635 
           
Changes in operating assets and liabilities:          
Prepaid expenses and other assets   74,414    1,156,128 
Accounts payable   84,783    (285,841)
Accrued expenses and other current liabilities   19,750    (128,347)
Related party payables   (1,327,278)   — 
Net cash used in operating activities   (10,104,256)   (4,828,985)
           
CASH FLOWS FROM INVESTING ACTIVITIES:          
Issuance of short-term note receivable   (1,850,000)   (1,809,500)
Purchase of digital assets   (338,102)   — 
Sales of digital assets   9,000,202    — 
Purchase of intangible assets   (715,187)   — 
Proceeds from settlement of short-term note receivable   100,000    — 
Net cash provided by/ (used in) investing activities   6,196,913    (1,809,500)
           
CASH FLOWS FROM FINANCING ACTIVITIES:          
Parent company equity held at cost   (12,000,000)   — 
Proceeds from the issuance of convertible debt   —    200,000 
Repayment of convertible debt   (132,000)   (132,000)
Proceeds from common stock issuances under ELOC facility   9,306    — 
Payment of ELOC commitment fee   (100,000)   — 
Repayment of promissory notes   —    (1,033,500)
Proceeds from issuance of promissory notes   —    3,295,000 
Net Proceeds from issuance of common and preferred shares in private placement   —    41,911,544 
Net cash (used in)/provided by financing activities   (12,222,694)   44,241,044 
           
Net change in cash and cash equivalents   (16,130,037)   37,602,558 
Cash and cash equivalents - beginning of period   19,332,707    1,174,608 
Cash and cash equivalents - end of period  $3,202,670   $38,777,166 
           
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION          
Cash paid during the period for:          
Interest   —    — 
Taxes   —    — 
           
NONCASH FINANCING AND INVESTING ACTIVITIES:          
Deemed dividend arising from warrant down-round provision   —   $867,796 
Issuance of common stock for conversion of Series B preferred shares  $27,965,251    — 
Issuance of warrants to placement agent   —   $5,340,491 
Issuance of common stock for the conversion of Series A-2 preferred shares   —   $5,057,361 
ELOC facility settled into equity  $3,915    — 
ELOC shares issued for subscription receivable  $2,039    — 
Accrued interest applied to the purchase of parent company equity  $2,192    — 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

6

 

 

FF EAI ROBOTICS ECOSYSTEM INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

 

NOTE 1 — BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES

 

Corporate History

 

Ritter Pharmaceuticals, Inc. (the Company’s predecessor) was formed as a Nevada limited liability company on March 29, 2004 under the name Ritter Natural Sciences, LLC. In September 2008, this company converted into a Delaware corporation under the name Ritter Pharmaceuticals, Inc. On May 22, 2020, upon completing a “reverse recapitalization” transaction with Qualigen, Inc., Ritter Pharmaceuticals, Inc. was renamed Qualigen Therapeutics, Inc. (the “Company”). Qualisys Diagnostics, Inc. was formed as a Minnesota corporation in 1996, reincorporated to become a Delaware corporation in 1999, and then changed its name to Qualigen, Inc. in 2000. Qualigen, Inc. was a wholly-owned subsidiary of the Company. On July 20, 2023, the Company sold all of the issued and outstanding shares of common stock of Qualigen, Inc. to Chembio Diagnostics, Inc. (“Chembio”), a wholly-owned subsidiary of Biosynex, S.A. (“Biosynex”). Following the consummation of this transaction, Qualigen, Inc. became a wholly-owned subsidiary of Chembio.

 

In 2022, the Company acquired a 52.8% interest in NanoSynex, Ltd. (“NanoSynex”). In 2023, the Company entered into an Amendment and Settlement Agreement with NanoSynex (the “NanoSynex Amendment”), which resulted in the Company losing its controlling interest in NanoSynex.

 

In September 2025, the Company entered into a subscription agreement (the “Subscription Agreement”) with certain investors, including Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) (“Faraday” or “FFAI”), pursuant to which the investors purchased $40.7 million (the “Offering”) of the Company’s common stock and shares of a newly created Series B Convertible Preferred Stock, par value $0.001 per share (the “Series B Preferred Stock”) (see Note 15 - Stockholders’ Equity). This Offering resulted in $37.7 million in net proceeds after $3.0 million in issuance costs were deducted. Up to $6.8 million of the net proceeds from the Offering were used to pay existing debt and fund the Company’s existing business operations. The remaining cash proceeds and contributed digital assets were originally intended to support the Company’s cryptocurrency treasury strategy. During the third quarter of 2026, the Company announced its planned exit from this strategy in connection with the acquisition of FFAI’s robotics business and its strategic focus on embodied artificial intelligence and robotics. As of September 30, 2026, the Company had disposed of substantially all of its digital asset holdings.

 

On November 14, 2025, the Company changed its corporate name from “Qualigen Therapeutics, Inc.” to “AIxCrypto Holdings, Inc.”

 

In January 2026, the Company formed three new wholly owned Delaware subsidiaries: AIxCrypto Token Labs US, Inc., AIxCrypto EAI, Inc., and AIxCrypto C10 ETF, Inc. These entities were formed to provide potential future organizational flexibility. AIxCrypto EAI, Inc., doing business as RoboShare, commenced commercial operations during the third quarter of 2026, and its accounts are consolidated.

 

In February 2026, the Company’s board of directors (the “Board”) approved a strategic realignment to concentrate exclusively on its Real-World Asset (“RWA”) tokenization and Embodied Artificial Intelligence (“EAI”) ecosystem, discontinuing development of the BesTrade DeAI Agent platform and C10 digital asset portfolio management tools. At that time, management continued to evaluate strategic alternatives for its remaining legacy therapeutic programs, including potential out-licensing or asset sale.

 

On May 21, 2026, following a comprehensive strategic review, the Board formally approved the discontinuation and structured wind-down of the Company’s entire legacy biotechnology business segment, marking the full termination of all historical biopharmaceutical and therapeutic operations. As of September 30, 2026, the Company held no remaining assets associated with these operations. No additional impairment charges, closure costs or other wind-down expenses were recognized during the three months ended September 30, 2026.

 

RoboShare launched publicly in June 2026 and delivered its first commercial event on August 29, 2026. It generated net marketplace commission and operating-service revenue during the third quarter of 2026; see Revenue Recognition below.

 

Effective September 30, 2026, the Company changed its legal name from “AIxCrypto Holdings, Inc.” to “FF EAI Robotics Ecosystem Inc.” Its common stock began trading on the Nasdaq Capital Market under the symbol FFR on that date. The name change did not change the reporting entity or historical financial statements.

 

7

 

 

Basis of Presentation

 

Certain information or footnote disclosures normally included in financial statements prepared in accordance with Generally Accepted Accounting Principles (“GAAP”) have been condensed or omitted, pursuant to the rules and regulations of the Securities and Exchange Commission for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results, and cash flows for the periods presented. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, which contains the audited financial statements and notes thereto. The financial information as of December 31, 2025 is derived from the audited financial statements presented in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025. The interim results for the three and nine months ended September 30, 2026 are not necessarily indicative of the results to be expected for the year ending December 31, 2026 or for any future periods.

 

Principles of Consolidation

 

The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. In general, the functional currency of the Company is the U.S. dollar. There were no foreign currency transactions in the three and nine months ended September 30, 2026 and 2025.

 

Accounting Estimates

 

Management uses estimates and assumptions in preparing its consolidated financial statements in accordance with U.S. GAAP. Those estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses. The Company’s estimates relate to the estimated fair value of convertible debt, warrant liabilities, and determination of the allowance for credit losses. Actual results could vary from the estimates that were used.

 

Related Parties and Related Party Transactions

 

A related party is a person who has the ability to exert significant influence over the Company and may include executive officers and directors, including members of their immediate families, stockholders owning more than 10% of the Company’s voting securities, or other entities deemed to be affiliates, as defined in Accounting Standards Codification (“ASC”) 850, Related Party Disclosures. The Company assesses its related parties and applicable disclosures on a quarterly basis, considering all relevant facts and circumstances.

 

Cash and Cash Equivalents

 

The Company considers all highly liquid investments purchased with an initial maturity of 90 days or less and money market funds to be cash equivalents.

 

The Company maintains the majority of its cash in accounts at banking institutions in the U.S. that are of high quality. Cash held in these accounts often exceed the Federal Deposit Insurance Corporation (FDIC) insurance limits. If such banking institutions were to fail, the Company could lose all or a portion of amounts held in excess of such insurance limitations. As of September 30, 2026, the Company had not experienced losses on these accounts, and management believes the Company is not exposed to significant risk on such accounts.

 

Digital Assets

 

The Company accounts for its digital assets in accordance with ASC 350, Intangibles—Goodwill and Other, as amended by Accounting Standards Update (“ASU”) 2023-08, Accounting for and Disclosure of Crypto Assets. The Company adopted ASU 2023-08 effective January 1, 2025. Digital assets held by the Company, including Bitcoin, Cardano, Chainlink, Ethereum, Native BNB, Ripple, Solana, Tether (USDT), and Tron, meet the scope criteria of ASU 2023-08 and are recognized as indefinite-lived intangible assets. These assets are initially recorded at cost, including transaction fees, upon obtaining control of the asset, and are measured subsequently at fair value with changes in value recognized in net income or loss. The Company uses a FIFO methodology to assign costs to digital assets for purposes of the digital assets held and realized gains and losses disclosures. Purchases and sales of digital assets that are not revenue arrangements are classified on the statement of cash flows as investing activities. Net loss on digital assets are adjusted in operating activities in the statement of cash flows. During the three months ended September 30, 2026, the Company disposed of substantially all of its digital asset holdings. As of September 30, 2026, the remaining digital assets had an immaterial aggregate fair value.

 

8

 

 

Revenue Recognition

 

The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers, when or as control of promised services is transferred to customers, in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those services. The Company identifies contracts with customers and the distinct performance obligations within each contract, determines the transaction price, allocates the transaction price to the performance obligations based on their relative standalone selling prices, and recognizes revenue when or as each performance obligation is satisfied.

 

Through its RoboShare platform, the Company facilitates bookings for robot services provided by equipment providers. The Company acts as an agent in these arrangements because it does not control the underlying provider services before they are transferred to customers. Accordingly, marketplace revenue is recognized on a net basis and consists of commissions calculated as a contractual percentage of the provider service price, excluding applicable taxes. The Company’s performance obligation is to arrange and facilitate the completion and settlement of a provider booking. Commission revenue is recognized at a point in time when the provider service has been completed and the applicable contractual acceptance, dispute and release conditions have been satisfied.

 

The Company also provides optional robot operating and production services, including choreography, operator deployment and related event support. These services are separately available and are distinct from the provider services arranged through the platform. The Company acts as principal for its operating and production services because it controls the promised service output before transfer to the customer and is responsible for its fulfillment and acceptability. Revenue from these services is presented on a gross basis and recognized over the service period as customers simultaneously receive and consume the benefits of the Company’s performance.

 

The transaction price reflects contractual discounts and estimated refunds, credits and other variable consideration. Variable consideration is included in the transaction price only to the extent that it is probable that a significant reversal of cumulative revenue recognized will not occur when the related uncertainty is resolved. Discounts are allocated to the performance obligations on a relative standalone selling price basis unless the criteria for allocation to a specific performance obligation are met. Sales taxes collected on behalf of taxing authorities are excluded from revenue.

 

Amounts received before the related performance obligations are satisfied, including deferred marketplace commissions and advance payments for operating and production services, are recorded as contract liabilities and recognized as revenue when the applicable revenue recognition criteria are met. Amounts collected on behalf of equipment providers are recorded as payables to those providers.

 

The Company evaluates robot service arrangements to determine whether they convey the right to control the use of identified equipment and therefore contain a lease within the scope of ASC 842, Leases. This assessment considers whether the customer has both the right to obtain substantially all of the economic benefits from the equipment’s use and the right to direct its use. The Company’s marketplace arranging services and operating and production services are accounted for under ASC 606.

 

Software Capitalization

 

The Company accounts for the costs incurred in developing its product offerings under ASC 350-40, Internal-Use Software.

 

In accordance with the guidance in ASC 350-40, the Company will capitalize costs incurred in connection with the development of the Company’s product offerings during the application development stage. Costs incurred during the preliminary project and post-implementation stages are expensed as incurred. Costs incurred in connection with maintenance activities, including training or bug fixes are also expensed as incurred. The Company stops capitalizing qualifying costs once development activities are completed and the project is ready for its intended use.

 

Capitalized software is presented within intangible assets and amortized on a straight-line basis over 36 months beginning when the software is ready for its intended use. The Company reviews useful lives and evaluates impairment when events or changes in circumstances indicate that carrying amounts may not be recoverable. Software under development that is no longer expected to be completed or used is evaluated under ASC 350-40; software in use is evaluated for recoverability and impairment under ASC 360. Cash payments for capitalized software are classified as investing activities. See Note 7 for additional information.

 

Derivative Financial Instruments and Warrant Liabilities

 

The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of its financial instruments, including issued stock purchase warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the unaudited condensed consolidated statements of operations and comprehensive loss. Depending on the features of the derivative financial instrument, the Company uses either the Black-Scholes option-pricing model or a Monte-Carlo simulation to value the derivative instruments at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period (See Note 9 – Warrant Liabilities).

 

9

 

 

Equity Line of Credit

 

The Company accounts for its equity line of credit (the “ELOC”) facility in accordance with ASC 815, Derivatives and Hedging, including ASC 815-40, Contracts in Entity’s Own Equity. The Company separately evaluates its right under the ELOC facility to initiate future purchases and each individual purchase commitment arising upon delivery of a valid purchase notice and satisfaction of the applicable contractual conditions. The Company’s right to initiate future purchases is evaluated as a separate financial instrument under ASC 815 and measured at fair value. The fair value of the unused draw option was de minimis as of September 30, 2026 and was not recorded on the condensed consolidated balance sheet.

 

Upon delivery of a valid purchase notice and satisfaction of the applicable contractual conditions, an individual purchase commitment is evaluated as a derivative instrument. The Company determined that these purchase commitments do not qualify for the own-equity scope exception under ASC 815-40 and therefore recognizes them as derivative liabilities at fair value when the related contractual obligations become binding. Changes in the fair value of these derivative liabilities are recognized in earnings until settlement or until the instruments otherwise qualify for equity classification under applicable accounting guidance. Upon settlement through the issuance of shares of common stock, the Company derecognized the related derivative liability and recorded the issuance of shares of common stock as common stock and additional paid-in capital. The Company measured the shares at fair value and recognized the difference between the fair value and the proceeds received pursuant to the discounted pricing terms as loss on ELOC the condensed consolidated statement of operations. The Company reassesses the classification of outstanding purchase commitments and related settlement provisions at each reporting date.

 

Nonrefundable commitment fees are expensed as incurred to the extent they are not allocated to a separately recognized asset or another identifiable transaction element. Receivables arising from completed issuance of common stock are generally presented as a deduction from stockholders’ equity. Such receivables may be presented as assets when collected in cash before the financial statements are issued and the applicable subsequent collection exception is met.

 

The Company reassesses the classification of outstanding purchase commitments and related settlement provisions at each reporting date. Shares transferred to a pre-delivery pool are distinguished from shares issued in connection with the completed subscriptions. A transfer to the pre-delivery pool, by itself, does not create a completed purchase or give rise to subscription receivable or an additional equity. The Company evaluates the legal issuance status and substantive rights associated with such share, including voting, transfer, economic and recall rights, in determining their presentation within stockholder’s equity and their treatment under ASC 260. The Company reconciles the legal share records with the completed purchases and pre-delivery pool shares. Shares subject to substantive recall arrangements are evaluated under ASC 260 based on the substance of the related rights and obligations before inclusion in basic loss per share.

 

Fair Value Measurements

 

The Company determines the fair value measurements of applicable assets and liabilities based on a three-tier fair value hierarchy established by accounting guidance and prioritizes the inputs used in measuring fair value. The Company discloses and recognizes the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements). The guidance establishes three levels of the fair value hierarchy as follows:

 

  ● Level 1 - Inputs that reflect unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date;
  ● Level 2 - Inputs other than quoted prices that are observable for the assets or liability either directly or indirectly, including inputs in markets that are not considered to be active; and
  ● Level 3 - Inputs that are unobservable.

 

Fair Value of Financial Instruments

 

Cash, prepaid expenses, and accrued liabilities are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments. Short-term notes receivable are valued subject to a current expected credit loss (“CECL”) model (see Note 6 - Short-Term Notes Receivable).

 

The value of the Company’s warrant liabilities as of September 30, 2026 and December 31, 2025 was determined using the Black-Scholes Model. Significant assumptions used in the valuation include the expected volatility of the Company’s common stock, the contractual term of the warrants, the risk-free interest rate, and an expected dividend yield of zero. Expected volatility is based on a blend of comparable public company data and, as available, the Company’s own historical volatility. The risk-free rate is derived from U.S. Treasury yields with maturities commensurate with the remaining contractual term of the warrants. Fair value measurements associated with the liability-classified warrants represent Level 3 valuations under the fair value hierarchy.

 

The fair value of derivative purchase commitments arising under the Company’s equity purchase facility is determined using valuation techniques appropriate to the contractual terms and the status of each commitment. Relevant inputs include the market price of the Company’s common stock, the share quantity, contractual pricing features, net proceeds and settlement timing. Once the share quantity and contractual net proceeds are fixed, fair value reflects the fair value of the committed shares less the contractual net proceeds.

 

The Company’s right to initiate future purchases is evaluated as a separate financial instrument under ASC 815 and measured at fair value. The assessment considers the Company’s discretion to initiate purchases under the ELOC facility, floating purchase pricing at 93% of the lowest daily VWAP within the contractual three-day pricing window, a 3% draw fee on the gross purchase amount, and the short pricing-to-settlement interval. Based on this assessment, the Company concluded that the fair value of this right was immaterial as of September 30, 2026, and accordingly recognized no material derivative asset.

 

The Company from time to time elects the fair value option to account for certain debt liabilities. Electing the fair value option allows the Company to initially and subsequently measure such liabilities at fair value rather than amortized cost and may be applied to debt liabilities that contain conversion or other features that would otherwise require bifurcation and mark to market accounting. Such debt liabilities will initially be measured using valuation techniques appropriate to the terms and expected life of the note. The Company expects to use Level 3 input to measure the fair value in subsequent periods.

 

Parent Company Equity Held at Cost

 

The Company maintains an entrusted investment arrangement with Gold King Arthur Holding Limited (“GKA”), an independent third-party fiduciary, pursuant to which GKA acquires, holds and manages equity securities of the Company’s majority stockholder, FFAI, for the Company’s economic benefit. Consistent with EITF Issue No. 98-2 and based on the parent-directed nature of the arrangement, the Company has elected an accounting policy to present its indirect investment in FFAI equity securities, including FFAI’s common stock, preferred stock and warrants, as parent company equity held at cost, a contra-equity account classified within stockholders’ equity and accounted for analogously to treasury stock at historical cost, with no subsequent remeasurement for fair value changes recognized in the condensed consolidated statements of operations; warrants issued in connection with the investment are an integral component of the integrated parent-directed transaction and do not represent a separate unit of account, so no portion of the aggregate subscription proceeds is allocated to the warrants and no separate warrant asset or liability is recognized, and any gain or loss upon future disposition, conversion or settlement of the underlying securities is recognized in the condensed consolidated statements of operations upon disposition.

 

10

 

 

Sales and Marketing

 

Sales and marketing expenses are expensed as incurred and primarily consist of direct costs associated with branding, promotional, co-creation, and publicity activities. The Company’s marketing initiatives focus on increasing brand awareness for its real-world asset tokenization and embodied AI Infrastructure activities. For the nine months ended September 30, 2026 and 2025, the Company’s sales and marketing expenses were $743,937 and nil, respectively.

 

Stock-Based Compensation

 

The Company accounts for share-based compensation granted to employees and nonemployees in accordance with ASC 718, Compensation—Stock Compensation. Equity-classified awards are measured at their grant-date fair value. The fair value of common stock awards is determined using the quoted market price of the Company’s common stock on the grant date. The fair value of stock options is estimated using the Black-Scholes option-pricing model, incorporating the market price of the underlying common stock, exercise price, expected term, expected volatility, risk-free interest rate and expected dividend yield. Compensation cost for employee awards subject solely to service-based vesting conditions is recognized on a straight-line basis over the requisite service period, generally the vesting period. The cost of nonemployee awards is recognized as the related goods or services are received, in the same manner as if the Company had paid cash for those goods or services.

 

Income Taxes

 

Deferred income taxes are recognized for temporary differences in the basis of assets and liabilities for financial statement and income tax reporting that arise due to net operating loss carry forwards, research and development credit carry forwards and from using different methods and periods to calculate depreciation and amortization, allowance for doubtful accounts, accrued vacation, research and development expenses, and state taxes. A provision has been made for income taxes due on taxable income and for the deferred taxes on the temporary differences. The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.

 

Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. Realization of the deferred income tax asset is dependent on generating sufficient taxable income in future years.

 

Recently Adopted Accounting Standards

 

There have been no recently adopted accounting pronouncements by the Company.

 

Recently Issued Accounting Standards Not Yet Adopted

 

In November 2024, the Financial Accounting Standards Board (the “FASB”) issued ASU 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, and in January 2025, the FASB issued ASU 2025-01, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date. The amendments require public business entities to disclose, for each relevant expense caption, specified natural expense categories, including purchases of inventory, employee compensation, depreciation and intangible asset amortization, as applicable, together with a qualitative description of remaining amounts. The amendments also require disclosure of the total amount of selling expenses and, in annual periods, the entity’s definition of selling expenses. The amendments are effective for the Company’s annual financial statements for the year ending December 31, 2027, and interim financial statements beginning with the first fiscal quarter of 2028, with early adoption permitted. The amendments are required to be applied prospectively, with retrospective application permitted. The Company is currently evaluating the impact of the amendments on its disclosures and related processes and controls.

 

In September 2025, the FASB issued ASU 2025-06, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software. The amendments remove references to software development project stages and require capitalization to begin when management has authorized and committed to funding the project and completion and intended use of the software are probable. In assessing these criteria, entities must consider significant development uncertainty. The amendments also clarify disclosure requirements for capitalized internal-use software costs and incorporate website development guidance into ASC 350-40. The amendments are effective for the Company beginning January 1, 2028, including interim periods within that year. Early adoption is permitted as of the beginning of an annual reporting period. The amendments may be applied using a prospective, modified or retrospective transition approach. The Company is currently evaluating the impact of the amendments on its consolidated financial statements and related disclosures.

 

In December 2025, the FASB issued ASU 2025-11, Interim Reporting (Topic 270): Narrow-Scope Improvements, which clarifies interim disclosure requirements resulting in a comprehensive list of interim disclosures that are required by GAAP, and includes a disclosure principle that requires the disclosure of events since the end of the last annual reporting period that have a material impact on the Company. ASU 2025-11 is effective for the Company’s interim financial statements beginning with the first fiscal quarter of the year ended December 31, 2028, with early adoption permitted. ASU 2025-11 may be applied either prospectively or retrospectively. The Company is evaluating the disclosure requirements related to the new standard.

 

In December 2025, the FASB issued ASU 2025-12, Codification Improvements, which contains 33 narrow technical corrections, clarifications and editorial updates across multiple ASC Topics, including guidance for earnings per share, accounting for treasury stock retirements, leases and financial instruments. The amendments are effective for annual reporting periods beginning after December 15, 2026, and interim periods within those fiscal years, with early adoption permitted. While most revisions are expected to have an immaterial impact on the Company’s condensed consolidated financial statements, the update includes clarifications to diluted earnings per share calculations for loss periods that will require retrospective application to prior comparative periods upon adoption. The Company is currently evaluating the full effect of this ASU but does not anticipate a material overall impact to its financial position, results of operations or disclosures.

 

The Company does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on its unaudited condensed consolidated financial statements or disclosures.

 

11

 

 

NOTE 2 — LIQUIDITY AND GOING CONCERN

 

The Company has incurred recurring operating losses and expects further losses. At September 30, 2026, accumulated deficit was approximately $153.0 million. Net cash used in operating activities for the nine months ended September 30, 2026 was approximately $10.1 million, compared with $7.0 million for the year ended December 31, 2025. At September 30, 2026, cash and cash equivalents were approximately $3.2 million, and remaining digital assets were approximately $2. Substantially all digital assets had been disposed of by quarter end.

 

Current liabilities were approximately $1.9 million at September 30, 2026, comprising $1.3 million of accounts payable, $0.3 million of related-party payables, $0.2 million of accrued expenses and other current liabilities, and $74,623 of warrant liabilities. Operating expenses during the three months ended September 30, 2026 were approximately $4.3 million. No debt for borrowed money was outstanding at quarter end. During the nine months ended September 30, 2026, the Company repaid $132,000 of convertible debt principal.

 

The Company expects to continue to have net losses and negative cash flow from operations, which will challenge its near-term liquidity. RoboShare began generating revenue during the third quarter of 2026, with revenue of $4,473 and $4,473 for the three and nine months ended September 30, 2026, respectively. These operations remain in the early stages of commercialization and have not generated sufficient recurring operating cash inflows to fund the Company’s operating requirements.

 

Management’s plans to mitigate liquidity constraints include continued operating expense discipline, commercialization of RoboShare, integration and development of the robotics business acquired from FFAI, the Company’s majority stockholder, and pursuit of strategic partnerships and additional equity or debt financing. On October 23, 2026, the Company completed its acquisition of FFAI’s robotics business. Management plans to expand the acquired business through robot sales, deployment and related services that complement RoboShare. The acquisition consideration consisted of equity securities, and the transaction did not itself provide cash proceeds to fund operations. Successful execution of these plans depends on customer demand, integration, fulfillment capabilities and sufficient operating funding. See Note 19 — Subsequent Events.

 

On October 12, 2026, the Company entered into a securities purchase agreement with certain investors for a private placement of the Company’s common stock (and, to the extent required by a beneficial ownership limitation, Series D non-voting convertible preferred stock) for aggregate gross proceeds of up to $10.0 million (the “PIPE”). The investors may fund their subscriptions on or before the fifteenth business day following that closing. The PIPE has no minimum aggregate funding condition, the net proceeds are to be used for the development and operations of the Company’s robotics business, and completion of the acquisition is not conditioned on the PIPE or any other financing. As of the date these condensed consolidated financial statements are issued, the PIPE have not closed, and the completion of the PIPE and any other financing is outside of the Company’s control. See Note 19 — Subsequent Events.

 

Management also plans to seek additional equity or debt financing, including private placements, public offerings and potential financial support from FFAI, and to utilize the Company’s equity purchase facility with GKA. The facility provides for purchases of up to $50.0 million of common stock, subject to contractual conditions. Actual proceeds depend on market prices, trading volume, available resale registration capacity, applicable ownership and issuance limitations and other contractual requirements. The undrawn commitment does not represent cash available to fund operations. See Note 15 — Stockholders’ Equity and Note 19 — Subsequent Events.

 

As a result, management’s plans are not considered probable of being effectively implemented and do not alleviate the substantial doubt about the Company’s ability to continue as a going concern. Accordingly, the Company’s limited liquidity, recurring operating losses, lack of sufficient recurring operating cash flows and dependence on additional financing collectively raise substantial doubt about its ability to continue as a going concern for the one-year period following the date these condensed consolidated financial statements are issued.

 

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The financial statements do not include any adjustments that would be necessary should the Company be unable to continue as a going concern, and therefore be required to liquidate its assets and discharge its liabilities in other than the normal course of business and at amounts that may differ from those reflected in the accompanying financial statements.

 

NOTE 3 — DIGITAL ASSETS

 

As part of its strategic realignment completed in the fourth quarter of 2025, the Company began acquiring digital assets for investment purposes and for use within its programmable technology infrastructure platform.

 

The Company held digital assets consisting of cryptocurrencies, stablecoins, and other blockchain-based tokens. During the three months ended September 30, 2026, the Company disposed of substantially all of its digital asset holdings. As of September 30, 2026, the remaining digital assets had an immaterial aggregate fair value.

 

Digital Asset Activity

 

The following table summarizes digital asset activity for the period indicated, including cost basis, fair value at the time of sale, realized and unrealized losses, and the fair value of outstanding digital assets as of September 30, 2026:

 

      
Balance at December 31, 2025  $10,250,497 
Additions(1)   338,102 
Dispositions(1)   (9,000,202)
Gains(2)   5,590,492 
Losses(2)   (6,841,048)
Payments made   (337,839)
Balance at September 30, 2026  $2 

 

(1) Additions represent purchases of crypto assets held for investment, dispositions represent liquidation of crypto assets held for investment.
(2)

The Company measures gains and losses by each asset held. These amounts include unrealized gains of $5,590,492, realized losses of $3,935,306, and unrealized losses of $2,905,742 during the nine months ended September 30, 2026.

 

The Company measures digital assets at fair value in accordance with ASC 820, Fair Value Measurement.

 

Fair value is determined using quoted prices in active markets for identical assets (Level 1 inputs). The Company utilizes pricing information provided by the principal market, which is based on observable market prices from active trading exchanges.

 

12

 

 

NOTE 4 — FAIR VALUE MEASUREMENTS

 

Below is the summary of the Company’s assets and liabilities measured at fair value on a recurring basis and categorized using the fair value hierarchy as of September 30, 2026:

 

   (Level 1)   (Level 2)   (Level 3)   Total 
Assets                    
Money Market funds  $2,777,996    —    —   $2,777,996 
Digital Assets   2    —    —    2 
Total Assets  $2,777,998    —    —   $2,777,998 
Liabilities                    
Convertible Debt   —    —    —    — 
Warrant Liabilities   —    —   $74,623   $74,623 
Total Liabilities   —    —   $74,623   $74,623 

 

Below is the summary of the Company’s assets and liabilities measured at fair value on a recurring basis and categorized using the fair value hierarchy as of December 31, 2025:

 

   (Level 1)   (Level 2)   (Level 3)   Total 
Assets                    
Money Market funds  $15,957,179    —    —   $15,957,179 
Digital Assets   10,250,497    —    —    10,250,497 
Total Assets  $26,207,676    —    —   $26,207,676 
Liabilities                    
Convertible Debt   —    —   $142,236   $142,236 
Warrant Liabilities   —    —    141,878    141,878 
Total Liabilities   —    —   $284,114   $284,114 

 

Equity Line of Credit

 

The Company accounts for binding purchases commitments arising under its ELOC facility as derivative liabilities measured at fair value, with changes in fair value recognized in earnings. The fair value of purchase commitments is determined based on the applicable contractual terms, including the number of shares subject to the commitment, the market price of the Company’s common stock, contractual pricing features, applicable draw fees and expected settlement timing. Once the number of shares and the contractual net proceeds for an individual purchase commitment were fixed, the fair value was measured as the fair value of the shares to be delivered less the contractual net proceeds, subject to the applicable settlement terms and other relevant valuation considerations.

 

During the nine months ended September 30, 2026, the Company recognized losses of $3,915, presented as loss on ELOC facility in the unaudited condensed consolidated statements of operations. All purchase commitments recognized as derivative liabilities during the period were settled through the issuance of shares of common stock by September 30, 2026. Accordingly, no derivative liability related to such purchase commitments remained outstanding at that date.

 

The Company’s right to initiate future purchases is evaluated as a separate financial instrument under ASC 815 and measured at fair value. The fair value of the its right to initiate future purchases was de minimis as of September 30, 2026 and was not recorded on the condensed consolidated balance sheet.

 

See Note 15 — Stockholders’ Equity for additional information regarding the equity purchase facility.

 

NOTE 5 — PREPAID INVESTMENT, PREPAID EXPENSES AND OTHER CURRENT ASSETS

 

Prepaid expenses and other current assets consisted of the following at September 30, 2026 and December 31, 2025:

 

   September 30,   December 31, 
   2026   2025 
Prepaid consulting, legal and other  $141,643   $461,337 
Prepaid insurance   317,394    481,338 
Prepaid legal   —    84,193 
Other current assets   2,039    1,638 
Prepaid expenses and other current assets  $461,076   $1,028,506 

 

NOTE 6 —SHORT-TERM NOTES RECEIVABLE

 

Short term notes receivable - consisted of the following at September 30, 2026 and December 31, 2025:

 

   September 30,   December 31, 
   2026   2025 
Short-term note receivable - Marizyme  $    -   $4,898,060 
Less allowance for credit losses   -    (4,555,000)
Short-term notes receivable  $-   $343,060 

 

13

 

 

As of December 31, 2025, the Company had advanced an aggregate of $4,166,900 to Marizyme, Inc. (“Marizyme”), against which Marizyme delivered demand promissory notes to the Company of like principal amounts (the “Marizyme Notes”). The Marizyme Notes bear at interest the rate of eighteen percent (18%) per annum. Marizyme may pre-pay all or any part of the outstanding principal or interest at any time and from time to time, in whole or in part, without premium or penalty. The total amortized cost consisting of principal and accrued interest was $4,898,060 as of December 31, 2025. For the nine months ended September 30, 2026, interest income of $275,358 was recognized within other income in the unaudited condensed consolidated statement of operations.

 

Under ASC 326-20, known as the current expected credit loss (“CECL”) model, the Company was required to estimate credit losses expected over the life of an exposure (or pool of exposures) based on historical information, current information, and reasonable and supportable forecasts. The Company is unable to use its historical data to estimate losses as it has no relevant loss history to date. To determine the estimate of expected credit losses, the Company used a probability-weighted approach that incorporates multiple settlement scenarios, including recovery of amounts due upon an acquisition of the debtor, and recovery in different liquidation scenarios, and determines the expected recoverable amount of the loan in each scenario. This model requires management to make certain assumptions including the likelihood of each outcome, the estimated value of the debtor’s assets, and the Company’s expected claim and recovery rate on the debtor’s assets in the event of an insolvency or a liquidation proceeding. During the nine months ended September 30, 2026, the Company recorded an additional allowance for credit losses of $142,574 and the total carrying value of the notes amounted to $475,844 prior to full settlement.

 

On May 12, 2026, the Company entered into a note purchase agreement (the “Note Purchase Agreement”) with CABG Acquisition Corp. (“CABG”), pursuant to which the Company sold all of its right, title, and interest in certain loans and related creditor rights relating to Marizyme. In consideration, the Company received $100,000 in cash, contingent royalty rights tied to product sales, and a 4.99% membership interest in CABG SPV, a dedicated New York limited liability company established solely by CABG to acquire and commercialize Marizyme’s operating assets and commercialize DuraGraft product. The Company received a one-time cash settlement of $100,000 from Marizyme in full satisfaction of all outstanding principal and accrued interest under the Marizyme Notes and recognized a loss on settlement of short-term note receivable of $375,844, which was classified within loss on settlement of short-term note receivable on the unaudited condensed consolidated statements of operations for the nine months ended September 30, 2026. The Company did not record any asset on its condensed consolidated balance sheet related to the royalty right or CABG SPV membership interest because royalties only activate after cumulative DuraGraft net revenue surpasses $20 million, the CABG SPV membership interest’s value depends on unproven commercialization, capital structure and dilution risks, and the Company no longer funds Marizyme’s biotech pipeline, making material future inflows highly unlikely under market-participant assumptions. No recurring impairment testing or third-party valuation assessments are required for these contingent upside interests, as their recoverable value is deemed zero at period end. Any royalty proceeds received in future periods will be recognized as other income upon actual cash receipt.

 

The Company is also party to a co-development agreement with Marizyme, dated April 11, 2024 (the “Co-Development Agreement”). The divestiture of debt claims does not alter the Company’s contractual rights under the Co-Development Agreement, including its right to future royalty-style payments once the contractual sales and launch milestones are met. See Note 14 - Research and License Agreements.

 

NOTE 7 — CAPITALIZED SOFTWARE

 

Capitalized software consists of development costs for the Company’s hosted platforms and is included in intangible assets in the condensed consolidated balance sheets. The carrying amounts were as follows:

 

  

September 30,

2026

  

December 31,

2025

 
Software under development  $860,546   $314,727 
Software in service   169,368    — 
Total capitalized software   1,029,914    314,727 
Less: accumulated amortization   (14,114)   — 
Less: impairment   (182,619)     
Capitalized software, net  $833,181   $314,727 

 

Software placed in service in July 2026 is amortized on a straight-line basis over 36 months. Amortization expense was $14,114 for both the three and nine months ended September 30, 2026 and was included in cost of revenue. Software under development is not amortized until it is ready for its intended use.

 

Estimated future amortization of software currently in service is $14,114 for the remainder of 2026, $56,456 in each of 2027 and 2028, and $28,228 in 2029. These estimates exclude software under development.

 

Following the Board-approved strategic realignment in February 2026, the Company ceased capitalization and wrote off approximately $182,619 of capitalized internal-use software development costs related to the BesTrade and C10 projects, which were determined to be abandoned and no longer probable of completion or future use.

 

NOTE 8 — ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES

 

Accrued expenses and other current liabilities consisted of the following at September 30, 2026 and December 31, 2025:

 

   September 30,   December 31, 
   2026   2025 
License fees  $—   $20,000 
Credit card   33,671    800 
Professional fees   109,500    115,434 
Employee benefits   5,958    - 
Other, including EAI customer liabilities   6,855    — 
Accrued expenses and other current liabilities  $155,984   $136,234 

 

NOTE 9 – WARRANT LIABILITIES

 

On November 20, 2024, the Company closed its private placement transaction resulting in the issuance of newly designated Series A-2 Preferred Stock (see Note 15 – Stockholders Equity). As a result of the issuance of a new class of voting securities, the Company evaluated its equity classified warrants’ respective terms, and concluded that warrants for 68,712 shares of common stock with a weighted average exercise price of $2.00 were required to be reclassified to liabilities, including pre-funded warrants with an exercise price of $0.05 per share. The pre-funded warrants are exercisable upon issuance and will remain exercisable until all the pre-funded warrants are exercised in full. At September 30, 2026, pre-funded warrants for 51,199 shares of common stock remained outstanding. During the nine months ended September 30, 2026 and 2025, the Company recorded a gain on change in fair value of warrant liabilities of $67,255 and a loss on change in fair value of warrant liabilities of $93,148, respectively, for these warrants. At September 30, 2026 and December 31, 2025, the fair value of these warrants was approximately $74,623 and $141,878, respectively.

 

14

 

 

The following table summarizes the activity in liability classified warrants for the nine months ended September 30, 2026:

 

    Common Stock Warrants  
    Shares    

Weighted– Average

Exercise Price

    

Range of Exercise Price

    

Weighted– Average

Remaining

Life (Years)

 
Total outstanding – December 31, 2025   67,218   $1.90     $0.05 - $7.80     3.68*
Granted   —    —    —    — 
Exercised   —    —    —    — 
Reclassified from equity   —    —    —    — 
Reclassified to equity   —    —    —    — 
Expired   —    —    —    — 
Total outstanding – September 30, 2026   67,218   $1.90    $0.05 - $7.80    2.94*
Exercisable   67,218   $1.90    $0.05 - $7.80    2.94*

 

*   excludes 51,199 pre-funded warrants which have no expiration date.

 

The following table summarizes the activity in liability classified warrants for the nine months ended September 30, 2025:

 

    Common Stock Warrants  
    Shares    

Weighted– Average

Exercise Price

    

Range of Exercise

Price

    

Weighted– Average

Remaining

Life (Years)

 
Total outstanding – December 31, 2024   68,712   $2.00     $0.05 - $7.80     4.32*
Granted   —    —    —    — 
Exercised   —    —    —    — 
Expired   (1,494)  $6.50     $6.50 - $6.50    — 
Total outstanding – September 30, 2025   67,218   $1.90     $0.05 - $7.80     3.94*
Exercisable   67,218   $1.90     $0.05 - $7.80     3.94*

 

* excludes 51,199 pre-funded warrants which have no expiration date.

 

The following table presents the Company’s fair value hierarchy for its warrant liabilities measured at fair value on a recurring basis as of September 30, 2026:

 

   Quoted Market   Significant         
   Prices for   Other   Significant     
   Identical   Observable   Unobservable     
   Assets   Inputs   Inputs     
Common Stock Warrant liabilities  (Level 1)   (Level 2)   (Level 3)   Total 
Balance as of December 31, 2025  $—   $—   $141,878   $141,878 
Granted   —    —    —    — 
Exercised   —    —    —    — 
Gain on change in fair value of warrant liabilities   —    —    (67,255)   (67,255)
Balance as of September 30, 2026  $—   $—   $74,623   $74,623 

 

15

 

 

The following table presents the Company’s fair value hierarchy for its warrant liabilities measured at fair value on a recurring basis as of December 31, 2025:

 

   Quoted Market   Significant         
   Prices for   Other   Significant     
   Identical   Observable   Unobservable     
   Assets   Inputs   Inputs     
Common Stock Warrant liabilities  (Level 1)   (Level 2)   (Level 3)   Total 
Balance as of December 31, 2024  $—   $—   $269,175   $269,175 
Granted   —    —    —    — 
Exercised   —    —    —    — 
Gain on change in fair value of warrant liabilities   —    —    (127,297)   (127,297)
Balance as of December 31, 2025  $—   $—   $141,878   $141,878 

 

There were no transfers of financial assets or liabilities between category levels for the nine months ended September 30, 2026 or the year ended December 31, 2025.

 

The value of the warrant liabilities was based on valuations internally generated Black Scholes valuations. Due to the nominal exercise price of the 2024 pre-funded warrants and indefinite term, the Company calculated an implied value of the 2024 pre-funded warrants based on the underlying common stock price on the valuation date, less the exercise price. For volatility, the Company considers comparable public companies as a basis for its expected volatility to calculate the fair value of common stock warrants and transitions to its own volatility as the Company develops sufficient appropriate history as a public company. The risk-free interest rate is based on U.S. Treasury notes with a term approximating the expected term of the common stock warrant. The Company uses an expected dividend yield of zero based on the fact that the Company has never paid cash dividends and does not expect to pay cash dividends in the foreseeable future. Any significant changes in the inputs may result in significantly higher or lower fair value measurements.

 

The following are the range of assumptions used in estimating the fair value of warrant liabilities as of September 30, 2026 and 2025:

 

   September 30, 2026   September 30, 2025 
   Range   Range 
Risk-free interest rate   4.99%   3.66% - 3.71%
Expected volatility (peer group)   130.0%   130.0% - 130.0%
Term of warrants (years)   2.94    3.94 - 5.00 
Expected dividend yield   0.00%   0.00%

 

NOTE 10 — CONVERTIBLE DEBT

 

2025 Convertible Note

 

On April 28, 2025, the Company entered into a secured convertible note (the “2025 Convertible Note”) with Alpha Capital Anstalt (“Alpha”), pursuant to which the Company issued to Alpha a non-interest-bearing note with a principal of $264,000, and an original issue discount (“OID”) of 20%, or $44,000, in exchange for $220,000 cash, less $20,000 in expenses. The 2025 Convertible Note is convertible at any time at Alpha’s option, into shares of the Company’s common stock at a price equal to $3.80 per share, subject to certain adjustments. The 2025 Convertible Note bears no interest, and the principal was due on January 28, 2026 (the “Maturity Date”).

 

The Company has determined the 2025 Convertible Note does not contain a substantial premium and therefore the Company elected to account for the 2025 Convertible Note under the fair value option in accordance with ASC 825-10-15-4. The Company determined the fair value of the 2025 Convertible Note was $311,943 at issuance. The difference between the $220,000 proceeds received and fair value was recorded as a loss upon issuance in the amount of $91,943. Issuance costs incurred in connection with the transaction were expensed immediately.

 

On June 4, 2025, the Company paid down $132,000 in principal at the request of Alpha, and on January 28, 2026, the remaining balance of $132,000 was paid. As of September 30, 2026, the remaining balance was zero, with a gain on the change in fair value of $10,236 recorded in the nine months ended September 30, 2026. As of December 31, 2025, the Company reassessed the fair value of the 2025 Convertible Note at $142,236, with a gain on the change in fair value of $37,707 recorded in the year ended December 31, 2025.

 

16

 

 

NOTE 11 — PROMISSORY NOTES

 

During the year ended December 31, 2025, the Company issued short term notes payable totaling $4.4 million for total net proceeds of $3.4 million. Over the course of the year, the Company repaid all notes for a total of $4.4 million, with the additional $1.0 million paid as a premium to some of the lenders and was recorded under interest expenses.

 

There were no outstanding promissory notes outstanding as of September 30, 2026 or December 31, 2025.

 

NOTE 12 — LOSS PER SHARE

 

Basic loss per share (“EPS”) is computed by dividing net loss including deemed dividends by the weighted-average number of shares of common stock outstanding plus unexercised pre-funded warrants. Diluted EPS is computed based on the sum of the weighted-average number of shares of common stock and potentially dilutive shares of common stock outstanding during the period. Potentially dilutive shares of common stock consist of shares issuable from preferred stock, convertible debt, stock options and warrants.

 

Shares Delivered in Advance of Settlement. Of the 4,044,975 shares of common stock registered for resale by the Investor under the Company’s registration statement on Form S-1 (File No. 333-297725), declared effective September 14, 2026, 13,000 shares were issued in settlement of VWAP purchases on or prior to September 30, 2026 and were purchased and paid for in accordance with a purchase agreement with GKA, and 4,031,975 shares were delivered to GKA in advance of settlement and remained unapplied at September 30, 2026. No consideration was paid or payable for the unapplied shares and no purchase or sale of those shares had occurred. The unapplied shares are issued and outstanding, and the Company may require their return at any time, in its sole discretion, without payment of any consideration. Because the unapplied shares are held solely to settle future purchases and may be recalled without consideration, the Company excludes them from basic and diluted weighted-average common shares outstanding until they are applied to a completed purchase. See Note 15 and Note 19.

 

   2026   2025   2026   2025 
  

For the Three Months Ended

September 30,

  

For the Nine Months Ended

September 30,

 
   2026   2025   2026   2025 
Net loss used for basic earnings per share  $(2,726,134)  $(2,037,819)  $(12,992,755)  $(6,369,407)
Basic weighted-average shares of common stock outstanding   20,787,933    620,694    16,307,498    1,662,223 
Dilutive potential shares issuable from preferred stock, convertible debt, stock options and warrants   —    —    —    — 
Diluted weighted-average shares of common stock outstanding   20,787,933    620,694    16,307,498    1,662,223 

 

These potentially dilutive securities have been excluded from diluted net loss per share as of September 30, 2026 and 2025 because their effect would be anti-dilutive:

 

   2026   2025 
   As of September 30, 
   2026   2025 
Shares of common stock subject to outstanding options   —    1,570 
Shares of common stock subject to outstanding warrants (excluding pre-funded warrants)   528,371    1,175,449 
Shares of common stock subject to outstanding preferred stock   2,102,850    20,054,987 
Shares of common stock subject to outstanding convertible debt   —    58,771 
Total common stock equivalents   2,631,221    21,290,777 

 

NOTE 13 — COMMITMENTS AND CONTINGENCIES

 

On July 29, 2026, the Company entered into a consulting agreement with Aibot US Operation Inc. (“Aibot”), effective July 16, 2026, pursuant to which Aibot will provide finance, capital markets, and human resources/legal coordination support services. The agreement has a one-year term ending July 15, 2027 and requires monthly consulting payments of $50,000, plus reimbursement of certain approved out-of-pocket expenses, for total consulting fees of $600,000 over the initial term. As of September 30, 2026, the Company had paid $250,000 under the agreement, of which $125,000 had been recognized as consulting expense for services received and $125,000 represented prepaid consulting fees for future services. The remaining unpaid contractual commitment was $350,000 as of September 30, 2026, excluding reimbursable expenses.

 

17

 

 

NOTE 14 — RESEARCH AND LICENSE AGREEMENTS

 

UCL Business Limited

 

On January 13, 2022, the Company entered into a license agreement with UCL Business Limited (“UCLB”) to obtain an exclusive worldwide in-license of a genomic quadruplex (G4)-selective transcription inhibitor drug development program which had been developed at University College London, including lead and back-up compounds, preclinical data and a patent estate. (UCLB is the commercialization company for University College London.) The program’s lead compound was being developed at the Company under the name QN-302 as a candidate for treatment for pancreatic ductal adenocarcinoma, which represents the vast majority of pancreatic cancers. The License Agreement required a $150,000 upfront payment, reimbursement of past patent prosecution expenses (approximately $160,000), and (if and when applicable) tiered royalty payments in the low to mid-single digits, clinical/regulatory/sales milestone payments and a percentage of any non-royalty sublicensing consideration paid to the Company.

 

On May 21, 2026, the Board approved the discontinuation and structured wind-down of the Company’s legacy biotechnology business segment following management’s evaluation of strategic alternatives for the segment, including a potential sale of the business. In connection with the wind-down of its legacy biotechnology business, the Company entered into a Deed of Termination and concurrent Assignment Agreement with UCLB, each effective July 9, 2026, pursuant to which: (i) the license agreement dated January 13, 2022, as amended, relating to G-Quadruplex binding molecules and the QN-302 program, was terminated in its entirety; and (ii) the Company assigned to UCLB all related intellectual property rights, including pre-clinical and clinical data, regulatory submissions, and the Investigational New Drug Application filed with the FDA, for a nominal consideration of £1.

 

There were no license costs recorded related to this agreement during the nine months ended September 30, 2026 and 2025.

 

QN-302 Phase 1 Study

 

In June 2023, the Company entered into a Master Clinical Research Services Agreement with Translational Drug Development, LLC (“TD2”) whereby TD2 agreed to perform certain clinical research and development services for the Company including but not limited to trial management, side identification and selection, site monitoring/management, medical monitoring, project management, data collection, statistical programming or analysis, quality assurance auditing, scientific and medical communications, regulatory affairs consulting and submissions, strategic consulting, and/or other related services. From time to time, the Company may enter into statements of work with TD2 for the performance of specific services under this Master Clinical Research Services Agreement.

 

In June 2023, the Company entered into a Master Laboratory Services Agreement with MLM Medical Labs, LLC (“MLM”) whereby MLM agreed to perform certain clinical research and development services for the Company including but not limited to laboratory, supply, testing, validation, data management, and storage services. From time to time, the Company may enter into work orders with MLM for the performance of specific services under this Master Laboratory Services Agreement.

 

In June 2023, the Company entered into a Master Services Agreement with Clinigen Clinical Supplies Management, Inc. (“Clinigen”) whereby Clinigen agreed to provide certain pharmaceutical products and/or services. From time to time, the Company may enter into statements of work with Clinigen for the performance of specific services under this Master Services Agreement.

 

In July 2023, pursuant to the above agreements, the Company entered into work orders and statements of work for clinical trial services for the conduct of the QN-302 Phase 1 study. Given the Company’s financial situation, the Company slowed the development of the QN-302 Phase 1 Study beginning in the second quarter of 2024.

 

On May 21, 2026, the Board approved the discontinuation and structured wind-down of the Company’s legacy biotechnology business segment following management’s evaluation of strategic alternatives for the segment, including a potential sale of the business. The QN-302 Phase 1 study is included within the scope of this discontinued legacy biotechnology business wind-down, and no further developments related to this clinical program occurred as of September 30, 2026.

 

18

 

 

Marizyme

 

On April 11, 2024, the Company entered into a Co-Development Agreement with Marizyme, which has been amended subsequently. Under the terms of the Co-Development Agreement, the Company committed to provide funding payments to Marizyme and pay a one-time exclusivity fee of $200,000. The $200,000 exclusivity fee and an initial $500,000 funding payment were remitted to Marizyme on April 12, 2024, and both amounts were recorded within research and development expenses on the unaudited condensed consolidated statements of operations and other comprehensive loss in the respective periods of payment. The exclusivity fee granted the Company an exclusive negotiating window through May 31, 2024 to negotiate a comprehensive strategic partnership covering Marizyme’s DuraGraft product line. The funding payments proceeds were intended to financially support the commercial rollout of Marizyme’s DuraGraft™ vascular conduit system, a device indicated for adult patients receiving coronary artery bypass graft surgery, used for flushing and preserving saphenous vein grafts for such procedures. In exchange for the funding contributions, the Company is entitled to quarterly revenue-based payments analogous to royalties equal to 33% of DuraGraft Net Sales (Net Sales defined consistently with gross profit derived from net product sales). The aggregate maximum amount of these royalty-like payments is capped at twice the total funding advanced by the Company. No royalty-like obligations accrue to Marizyme, and no payments to the Company are required, until two thresholds are satisfied: DuraGraft achieves commercial launch in the United States, and cumulative U.S. Net Sales of DuraGraft reach $500,000.

 

As of the September 30, 2026 and 2025, neither of the above triggering conditions had been satisfied, and no royalty-related payments were payable or receivable by the Company. Separately, in May 2026, the Company completed the sale and full assignment of all its outstanding loan and creditor interests in Marizyme pursuant to the Note Purchase Agreement; this divestiture of debt claims does not alter the Company’s contractual rights under the Co-Development Agreement, including its right to future royalty-style payments once the contractual sales and launch milestones are met.

 

NOTE 15 — STOCKHOLDERS’ EQUITY 

 

As of September 30, 2026 and 2025, the Company had two classes of authorized capital stock: common stock and preferred stock.

 

Common Stock

 

Holders of common stock generally vote as a class with the holders of the preferred stock and are entitled to one vote for each share held. Subject to the rights of the holders of the preferred stock to receive preferential dividends, the holders of common stock are entitled to receive dividends when and if declared by the Board. Following payment of the liquidation preference of the preferred stock, any remaining assets will be distributed ratably among the holders of the common stock and, on an as-if-converted basis, the holders of any preferred stock upon liquidation, dissolution or winding up of the affairs of the Company. The holders of common stock have no preemptive, subscription or conversion rights and there are no redemption or sinking fund provisions.

 

At September 30, 2026, the Company had reserved 3,329,409 shares for possible future issuance as follows:

 

      
Conversion of Series A-2 preferred stock   267,587 
Conversion of Series B preferred stock   1,835,263 
Exercise of stock warrants   1,226,559 
Total   3,329,409 

 

Faraday Subscription Agreement

 

As described in Note 1 – Business and Summary of Significant Accounting Policies and Estimates, on September 29, 2025, the Company consummated the financing with certain investors, including Faraday, pursuant to the Subscription Agreement, and the Company issued and sold 337,432 shares of the Company’s common stock and issued 100,000 shares to the Company’s legal firm. The purchase price of the common stock was $2.246 per share for an aggregate $0.8 million.

 

Additionally, in connection with the closing, the Company issued 60,257 shares of common stock as compensation to its advisor which has been accounted for under ASC 718 Compensation—Stock Compensation (See Note 1 – Organization and Summary of Significant Accounting Policies and Estimates).

 

Further, in connection with the closing, 1,087,266 warrants (the “Placement Agent Warrants”) were issued to the placement agent. The Placement Agent Warrants were immediately exercisable and have an initial exercise price of $2.47 per share. At September 30, 2026, 1,087,266 Placement Agent Warrants remained outstanding.

 

19

 

 

2024 Common Stock Purchase Agreement

 

On November 19, 2024, the Company entered into a common stock purchase agreement (the “Common Stock Purchase Agreement”) with Horberg Enterprises LP (the “Horberg”), pursuant to which the Company in its sole discretion has the right, but not the obligation, to issue and sell to Horberg up to $10.0 million of the Company’s common stock, from time to time beginning on the Commencement Date, as discussed below, subject to certain limitations and conditions detailed in the Common Stock Purchase Agreement. The Company is not obligated to sell any shares to Horberg under the Common Stock Purchase Agreement; sales and timing of any sales of the Company’s common stock are solely at the Company’s election. In accordance with the terms of the Common Stock Purchase Agreement, the Commencement Date is subject to certain conditions, including the effectiveness of a registration statement on Form S-1 or a similar prospectus permitting Horberg to offer and resell the shares of common stock acquired under the Common Stock Purchase Agreement.

 

No upfront fees were paid to Horberg at the execution of the arrangement. As of September 30, 2026, no registration statement had been filed and thus the Commencement Date permitting the sale of shares under the Common Stock Purchase Agreement had not yet occurred.

 

The Company evaluated the Common Stock Purchase Agreement under ASC 815-40 Derivatives and Hedging-Contracts on an Entity’s Own Equity as it represents the right to require Horberg to purchase shares of common stock in the future, similar to a put option. The Company concluded the Common Stock Purchase Agreement represents a freestanding derivative instrument that does not qualify for equity classification and therefore requires fair value accounting. The Company analyzed the terms of the contract and concluded the derivative instrument had no value at inception, as of September 30, 2026, or as of December 31, 2025.

 

Preferred Stock

 

There are a total of 15,000,000 shares of preferred stock authorized, of which 7,000 shares are designated as Series A-2 Preferred Stock, 10,000 shares are designed as Series A-3 Preferred Stock, and to 500,000 shares are designated as Series B Preferred Stock.

 

As described in Note 1 – Organization and Summary of Significant Accounting Policies and Estimates, on September 29, 2025, pursuant to the Subscription Agreement, the Company issued 39,943 shares of the newly designated Series B Preferred Stock, for $1,000 per share, for aggregate gross proceeds of approximately $39.9 million, before deducting placement agent fees and other offering expenses. The offering triggered a down-round provision of the Series A-2 Convertible Preferred Stock and Series A-3 Convertible Preferred Stock, as described further below, which resulted in a lower conversion price. As a result, the Company recorded a $2.0 million deemed dividend in the amount equal to the change in fair value of the abovementioned series of convertible preferred stock before and after the anti-dilution adjustment.

 

On July 28, 2025, in a private placement transaction, the Company sold and issued to certain institutional and accredited investors 4,500 shares of Series A-3 Convertible Preferred Stock, par value $0.001 per share, (the “Series A-3 Preferred Stock”), at a purchase price of $1,000 per share, for aggregate gross proceeds of approximately $4.5 million before deducting placement agent fees and offering expenses of $0.2 million, resulting in net proceeds of $4.3 million. The offering triggered a down-round provision of the Series A-2 Convertible Preferred stock, as described further below, which resulted in a lower conversion price. As a result, the Company recorded a $0.6 million deemed dividend in the amount equal to the change in fair value of the aforementioned series of convertible preferred stock before and after the anti-dilution adjustment.

 

On November 20, 2024, in a private placement transaction, the Company sold and issued to certain institutional and accredited investors 5,102 shares of the newly designated Series A-2 Convertible Preferred Stock, par value $0.001 per share (the “Series A-2 Preferred Stock” and together with the Series A-3 Preferred Stock, the “Series A Preferred Stock”), at a purchase price of $1,000 per share, for an aggregate purchase price of $5.1 million. The Company also entered into an exchange agreement with Yi Hua Chen on November 18, 2024, pursuant to which it issued 1,154 shares of Series A-2 Preferred Stock in full settlement of the outstanding balance of the 2024 Chen Debenture of approximately $1.15 million. During the year ended December 31, 2025, 5,656 shares of Series A-2 Convertible Preferred Stock and 4,500 shares of Series A-3 Convertible Preferred Stock were converted into 3,926,263 shares of common stock at a conversion price ranging from $3.64 to $2.246. During the nine months ended September 30, 2026, 35,821 shares of Series B Convertible Preferred Stock were converted into15,948,501 shares of common stock at a conversion price of $2.246. At September 30, 2026, the Company’s outstanding preferred stock consisted of the following:

 

   Authorized Shares   Outstanding Shares   Conversion Price  

Common Stock

Equivalent

 
Series A-2   7,000    601   $2.246    267,587 
Series B   500,000    4,122   $2.246    1,835,263 

 

20

 

 

The shares of Series A-2 Preferred Stock, Series A-3 Preferred Stock, and Series B Preferred Stock have the rights, preferences, powers, restrictions and limitations as set forth below.

 

Conversion Rights – Each share of preferred stock is convertible at any time, at the option of the holder, into a number of shares of common stock equal to $1,000 (the “Stated Value”), divided by a conversion price (the “Conversion Price”) initially equal to $3.64 for each share of Series A-2 Preferred Stock, $2.80 for each share of Series A-3 Preferred Stock and $2.246 for each share of Series B Preferred Stock (the “Conversion Shares”), subject to adjustment for any stock splits, stock dividends and similar events.

 

The Conversion Prices of the Series A Preferred Stock are also subject to down-round adjustments if the Company at any time while the Series A Preferred Stock is outstanding issues common stock or common stock equivalents at a lower effective price per share than the then-effective Conversion Price, in all cases subject to a floor price of $1.82 and $1.40 for the Series A-2 Preferred Stock and the Series A-3 Preferred Stock, respectively. Conversion of the Series A Preferred Stock will be prohibited if, as a result of such conversion, the holder, together with its affiliates, would beneficially own more than 4.99% (or 9.99% at the option of the holder) of the total number of shares of the Company’s common stock issued and outstanding.

 

Liquidation Preference – Upon any voluntary or involuntary liquidation, dissolution or winding-up of the Company, the holders of Series A Preferred Stock shall be entitled to an amount equal to the Stated Value for each share of Series A-2 Preferred Stock before any distribution or payment shall be made to the holders of common stock. Upon any voluntary or involuntary liquidation, dissolution or winding-up of the Company, the holders of Series B Preferred Stock shall be entitled to an amount equal to the Stated Value, plus any accrued and unpaid dividends thereon before any distribution or payment shall be made to the holders of common stock.

 

Voting Rights – The holders of Series A Preferred Stock are entitled to vote, together as a single class with the common stock, on all matters presented to the common stockholders for a vote. Each share of preferred stock is entitled to a number of votes equal to the number of shares into which such share of preferred stock would be convertible, as of the record date for determination of stockholders entitled to vote as to such matter, if the conversion price was equal to the “Minimum Price” (as defined in Nasdaq Listing Rule 5635(d)) as of the original issue date of the Series A Preferred Stock, taking into account for such purposes the beneficial ownership limitation as then in effect. The holders of Series B Preferred Stock will vote together with common stock on an as-converted basis.

 

Dividends – The holders of Series A Preferred Stock and Series B Preferred Stock are entitled to receive dividends, if and when such dividends are paid to holders of common stock, in the same form and at the same time on an as-converted to common stock basis.

 

Protective Provisions – At all times while the Series A Preferred Stock and Series B Preferred Stock are outstanding, without the consent of the holders of at least 67% of the Stated Value of each series of the then-outstanding Series A Preferred Stock and holders of at least 75% of the Stated Value of the then-outstanding Series B Preferred Stock, (the “Required Consent”), the Company is prohibited from amending its charter documents in any manner that adversely affects the rights of the Series A Preferred Stock and Series B Preferred Stock, repurchase junior securities of the Company, pay cash dividends or distributions on junior securities of the Company, or enter into a material transactions with an affiliate of the Company (unless it is at arm’s length and expressly approved by a majority of the disinterested directors). Without the Required Consent of the Series B Preferred Stock, the Company is prohibited from entering into, creating, assuming or guaranteeing any new indebtedness or liens of any kind.

 

In addition, as long as any shares of Series B Preferred Stock are outstanding, the Company shall not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series B Preferred Stock directly and/or indirectly (a) alter or change adversely the powers, preferences or rights given to the Series B Preferred Stock or alter or amend its corresponding Certificate of Designation, (b) authorize or create any class of stock ranking as to redemption or distribution of assets upon a liquidation senior to, or otherwise pari passu with, the Series B Preferred Stock or, authorize or create any class of stock ranking as to dividends senior to, or otherwise pari passu with, the Series B Preferred Stock, (c) amend its Certificate of Incorporation or other charter documents in any manner that adversely affects any rights of the holders of the Series B Preferred Stock, (d) increase the number of authorized shares of Series B Preferred Stock, or (e) enter into any agreement with respect to any of the foregoing.

 

Upon any subsequent issuance by the Company or any of its subsidiaries of common stock or common stock equivalents for cash consideration, indebtedness or a combination of units thereof (a “Subsequent Financing”), holders of Series B Preferred Stock may elect, in its sole discretion, to exchange (in lieu of conversion), if applicable, all or some of the shares of Series B Preferred Stock then held for any securities or units issued in a Subsequent Financing on a $1.00 for $1.00 basis. Additionally, if in such Subsequent Financing there are any contractual provisions or side letters that provide terms more favorable to the investors than the terms previously provided to holders of the Series B Preferred Stock, holders of the Series B Preferred Stock shall become a part of the transaction documents, at their option.

 

21

 

 

Equity Line of Credit with GKA

 

On June 16, 2026, the Company entered into a purchase agreement in connection to common stock with GKA for the ELOC arrangement, pursuant to which the Company has the right to issue and sell up to $50.0 million in aggregate gross purchase price of shares of common stock, subject to the terms and conditions of the agreement. The purchase price equals 93% of the lowest daily volume-weighted average price during the three trading days ending on the purchase date. GKA retains an additional draw fee equal to 3% of the gross purchase proceeds, which further reduces the net proceeds payable to the Company. Purchases under the ELOC arrangement are subject to a 9.99% beneficial ownership limitation and applicable Nasdaq issuance limitations.

 

On September 14, 2026, the Company filed a prospectus covering the resale by GKA of up to 4,044,975 shares of common stock issuable under the agreement. Such number represents the 19.99% exchange cap applicable to issuances without the requisite stockholder approval. On July 28, 2026, the Company obtained stockholder approval by written consent for issuances exceeding the exchange cap. The Company filed the related definitive information statement on September 4, 2026. Such approval becomes effective no earlier than 20 calendar days after the information statement is first sent or given to stockholders.

 

The ELOC agreement terminates upon the earliest of (i) the first day of the month following the 24-month anniversary of the effective date of the initial registration statement, (ii) purchases by GKA reaching the $50.0 million aggregate commitment, (iii) the Company’s common stock ceasing to be listed or quoted on an eligible principal market, or (iv) specified bankruptcy or insolvency events, subject to the terms of the agreement.

 

During the three months ended September 30, 2026, the Company completed four purchases under the ELOC agreement and issued an aggregate of 13,000 shares of common stock for aggregate gross proceeds of $11,696. After deduction of draw fees of $351, the net contractual proceeds were $11,345, of which the Company received $9,306 in cash by September 30, 2026. The Company collected the remaining $2,039 in full in cash in early October 2026, before the issuance of these unaudited condensed consolidated financial statements. Accordingly, the Company included the $2,039 receivable in prepaid expenses and other current assets at September 30, 2026. The Company accounted for the binding purchase commitments as derivative liabilities measured at fair value until settlement. During the nine months ended September 30, 2026, the Company recognized non-cash losses of $3,915 from changes in the fair value of these derivative liabilities, which were presented as loss on ELOC arrangement in the condensed consolidated statements of operations. Upon settlement of the completed purchases, the Company recorded an aggregate increase of $15,260 in common stock and additional paid-in capital. No derivative liability relating to those completed purchases remained outstanding at September 30, 2026. During the nine months ended September 30, 2026, the Company recognized the nonrefundable $100,000 commitment fee as expense, presented separately as ELOC commitment fee in the condensed consolidated statements of operations.

 

As of September 30, 2026, the Company had delivered an aggregate of 4,044,975 shares in connection with the agreement, including the 13,000 shares associated with completed purchases. The remaining 4,031,975 shares were delivered in advance to facilitate the settlement of potential future purchases. Until a valid purchase notice is delivered and the related purchase conditions are satisfied, GKA is not entitled to vote, sell, transfer or pledge the pre-delivered shares, has no economic interest in them, and must return them to the Company upon request. These terms are confirmed in a letter agreement described in Note 19. Shares transferred to a pre-delivery pool are distinguished from shares issued in connection with the completed subscriptions. A transfer to the pre-delivery pool, by itself, does not create a completed purchase or give rise to subscription receivable or an additional equity. The 4,031,975 shares delivered to GKA in advance of settlement and unapplied at September 30, 2026 are excluded from the weighted average number of shares outstanding used to compute basic and diluted net loss per share, as the Company may require their return at any time without payment of consideration and no consideration has been received for them.

 

The Company evaluates the legal issuance status and substantive rights associated with such share, including voting, transfer, economic and recall rights, in determining their presentation within stockholder’s equity and their treatment under ASC 260. The Company reconciles the legal share records with the completed purchases and pre-delivery pool shares. Shares subject to substantive recall arrangements are evaluated under ASC 260 based on the substance of the related rights and obligations before inclusion in basic EPS.

 

As of September 30, 2026, the Company had 26,358,983 shares of common stock issued and outstanding, including the 4,031,975 pre-delivered shares held by GKA subject to the Company’s unconditional recall right. Excluding the pre-delivered shares, 22,327,008 shares of common stock were outstanding for purposes of computing net loss per share.

 

Stock Options and Warrants

 

Stock Options

 

The Company recognizes all compensatory share-based payments as compensation expense over the service period, which is generally the vesting period.

 

In April 2020, the Company adopted the 2020 Stock Incentive Plan (the “2020 Plan”), which provides for the granting of incentive or non-statutory common stock options and other types of awards to qualified employees, officers, directors, consultants and other service providers.

 

In October 2025, the Company adopted the 2025 Equity Incentive Plan (the “2025 Plan”), which provides for the granting of incentive or non-statutory common stock options and other types of awards to qualified employees, officers, directors, consultants and other service providers. As of September 30, 2026, no awards were granted or outstanding under the 2025 Plan.

 

22

 

 

Equity Classified Compensatory Warrants

 

As part of the May 2020 reverse recapitalization transaction, the Company issued equity classified compensatory common stock warrants to an advisor and its designees. In addition, various service providers hold equity classified compensatory common stock warrants issued in 2017 and earlier (originally exercisable to purchase Series C convertible preferred stock, and now instead exercisable to purchase common stock). These are to be differentiated from the Series C Warrants described in Note 9 - Warrant Liabilities. As of September 30, 2026, warrants to purchase 71 shares of the Company’s common stock remained outstanding.

 

No new compensatory warrants were issued during the nine months ended September 30, 2026 or 2025.

 

The following table summarizes the equity classified compensatory warrant activity for the nine months ended September 30, 2026:

 

   Common Stock  
   Shares  

Weighted–Average

Exercise Price

  

Range of

Exercise Price

  

Weighted–Average

Remaining

Life (Years)

 
Total outstanding – December 31, 2025   160   $1,270.25    $1,270.25-$1,270.25    0.81 
Exercised   —    —    —    — 
Expired   (89)   —    —    — 
Forfeited   —    —    —    — 
Total outstanding – September 30, 2026   71   $1,270.25    $1,270.25-$1,270.25    0.61 
Exercisable   71   $1,270.25    $1,270.25-$1,270.25    0.61 
Non-Exercisable   —    —    —    — 

 

The following table summarizes the equity classified compensatory warrant activity for the nine months ended September 30, 2025:

 

   Common Stock 
   Shares  

Weighted–Average

Exercise Price

  

Range of

Exercise Price

  

Weighted–Average

Remaining

Life (Years)

 
Total outstanding – December 31, 2024   509   $1,270.25    $1,270.25-$1,270.25    0.69 
Exercised   —    —    —    — 
Expired   (349)  $1,270.25    $1,270.25-$1,270.25    — 
Forfeited   —    —    —    — 
Total outstanding – September 30, 2025   160   $1,270.25    $1,270.25-$1,270.25    1.06 
Exercisable   160   $1,270.25    $1,270.25-$1,270.25    1.06 
Non-Exercisable   —    —    —    — 

 

There were no compensation costs related to outstanding warrants for the nine months ended September 30, 2026 and 2025. As of September 30, 2026 and 2025, there was no unrecognized compensation cost related to nonvested warrants.

 

23

 

 

Noncompensatory Equity Classified Warrants

 

On December 22, 2022, in conjunction with the issuance of a debenture to Alpha (see Note 10 – Convertible Debt), the Company issued to Alpha a warrant (the “2022 Alpha Warrant”) to purchase 50,000 shares of the Company’s common stock. The exercise price of the 2022 Alpha Warrant was initially $82.50, and may be exercised in whole or in part, on or after June 22, 2023 and at any time before June 22, 2028. On December 5, 2023, the Company entered into an Amendment No. 1 with regard to the related Securities Purchase Agreement, with Alpha. This amendment reduced the exercise price of the 2022 Alpha Warrant from $82.50 per share to $36.50 per share. The amendment also revised certain provisions of the 2022 Alpha Warrant which resulted in reclassification of the 2022 Alpha Warrant from liabilities to equity during the year ended December 31, 2023. During the year ended December 31, 2024, the 2022 Alpha Warrant was partially exercised for 31,998 shares, and as of September 30, 2026, the 2022 Alpha Warrant to purchase 18,002 shares of the Company’s common stock remained outstanding.

 

On February 27, 2024, the Company entered into a new Securities Purchase Agreement with Alpha for the purchase of the February 2024 Debenture (see Note 10 – Convertible Debt). This Securities Purchase Agreement resulted in the reduction of the exercise price of the 2022 Alpha Warrant and the May 2020 warrant from $36.50 per share to $13.00 per share. The Company recognized a deemed dividend of $60,017, which represents the incremental fair value of the outstanding warrants as a result of the down-round provision. As the Company has an accumulated deficit, the deemed dividend was recorded as a reduction in additional paid-in capital, resulting in a net impact of zero to additional paid-in capital in the unaudited condensed consolidated statements of changes in stockholders’ equity. In addition, on February 27, 2024, the Company issued to Alpha a warrant (the “2024 Alpha Warrant”) to purchase 18,001 shares of the Company’s common stock at an exercise price of $13.00 per share, which may be exercised in whole or in part, at any time before February 27, 2029.

 

On September 6, 2024, as a result of the down-round provision triggered by shares sold in a public offering, the above warrants were repriced from $13.00 per share exercise price to $6.50 per share exercise price. The Company recognized an additional deemed dividend of $27,587, which represents the incremental fair value of the outstanding warrants as a result of the down-round provision. As the Company has an accumulated deficit, the deemed dividend was recorded as a reduction in additional paid-in capital, resulting in a net impact of zero to additional paid-in capital in the unaudited consolidated statements of changes in stockholders’ equity.

 

On April 12, 2024, in connection with the issuance of a convertible debenture to Yi Hua Chen (see Note 10 – Convertible Debt), the Company issued a liability classified warrant to Yi Hua Chen to purchase 36,001 shares of common stock, exercisable until February 27, 2029. On September 6, 2024, as a result of a down-round provision triggered by shares sold in a public offering, the warrant was repriced from an exercise price of $13.00 per share to an exercise price of $6.50 per share. The warrant was initially liability classified due to an insufficient number of authorized shares to settle the warrant prior to the receipt of stockholder approval, which was subsequently obtained on October 25, 2024. As of that date, the Company determined that stockholder approval resulted in equity classification for the warrant and accordingly, the Company remeasured the warrant liability to fair value, and reclassified to noncompensatory equity classified warrants.

 

On September 6, 2024 as a result of the down-round provision triggered by shares sold in a public offering, the above warrants were repriced from $13.00 per share exercise price to $6.50 per share exercise price. The Company recognized an additional deemed dividend of $27,587, which represents the incremental fair value of the outstanding warrants as a result of the down-round provision. As the Company has an accumulated deficit, the deemed dividend was recorded as a reduction in additional paid-in capital, resulting in a net impact of zero to additional paid-in capital.

 

As a result of a partial voluntary conversion of the 2024 Alpha Debenture on September 9, 2024, the Company no longer had sufficient shares to settle the 2024 Alpha Warrant in full until stockholder approval was obtained, and a portion (2,314 warrant shares with a fair value of $14,997) was reclassified to liabilities (see Note 9 – Warrant Liabilities). Stockholder approval was subsequently obtained on October 25, 2024, and as of that date, the Company determined that stockholder approval resulted in equity classification for the warrant again and, accordingly, the Company remeasured the warrant liability to fair value, and reclassified to noncompensatory equity classified warrants.

 

On September 6, 2024, upon the closing of a public offering, the Company issued pre-funded warrants to purchase 239,456 shares of common stock at a price of $6.45 per share with an exercise price of $0.05 per share (the “pre-funded warrants”). The pre-funded warrants are exercisable upon issuance and will remain exercisable until all the pre-funded warrants are exercised in full. Pre-funded warrants for 188,257 shares of common stock were exercised during the year ended December 31, 2024. At September 30, 2026 pre-funded warrants for 51,199 shares of common stock remained outstanding.

 

24

 

 

On September 6, 2024, upon the closing of a public offering, 16,019 warrants were issued to the placement agent. These warrants were not exercisable until March 5, 2025 and expire on September 6, 2029.

 

On November 20, 2024, the Company closed its private placement transaction resulting in the issuance of newly designated Series A-2 Preferred Stock. As a result of the issuance of a new class of voting securities, the Company evaluated its equity classified compensatory warrants’ respective terms, and concluded that compensatory warrants to purchase 1,353 shares of common stock with a weighted average exercise price of $6.50 and a fair value of $904 were required to be reclassified to liabilities as of November 20, 2024.

 

On April 28, 2025, as a result of the down-round provision triggered by the issuance of the 2025 Convertible Note (see Note 10 - Convertible Debt), warrants for 54,002 shares of common stock were repriced from $6.50 per share exercise price to $5.82 per share exercise price. The company recognized a deemed dividend of $1,586, which represents the incremental fair value of the outstanding warrants as a result of the down-round provision. As the Company has an accumulated deficit, the deemed dividend was recorded as a reduction in additional paid-in capital, resulting in a net impact of zero to additional paid-in capital in the unaudited condensed consolidated statements of changes in stockholders’ equity.

 

As discussed above, on September 29, 2025, 1,087,266 Placement Agent Warrants were issued. The Placement Agent Warrants were immediately exercisable and have an initial exercise price of $2.47 per share. At September 30, 2026, 1,087,266 Placement Agent Warrants remained outstanding.

 

The following table summarizes the noncompensatory equity classified warrant activity for the nine months ended September 30, 2026:

 

    Common Stock 
    Shares    

Weighted–

Average

Exercise Price

    

Range of

Exercise Price

    

Weighted–

Average

Remaining

 Life (Years)

 
Total outstanding – December 31, 2025   1,159,270   $2.72     $2.47 — $6.50     4.64 
Granted   —    —    —    — 
Exercised   —    —    —    — 
Expired   —    —    —    — 
Forfeited   —    —    —    — 
Total outstanding – September 30, 2026   1,159,270   $2.72     $2.47 — $6.50     3.89 
Exercisable   1,159,270   $2.72     $2.47 — $6.50     3.89 
Non-Exercisable   —    —    —    — 

 

The following table summarizes the noncompensatory equity classified warrant activity for the nine months ended September 30, 2025:

 

   Common Stock 
   Shares  

Weighted–

Average

Exercise Price

  

Range of

Exercise Price

  

Weighted–

Average

Remaining

 Life (Years)

 
Total outstanding – December 31, 2024   72,004   $6.50     $6.50 — $6.50     3.99 
Granted   1,087,266    2.47    $2.47 — $2.47    5.00 
Exercised   —    —    —    — 
Expired   —    —    —    — 
Forfeited   —    —    —    — 
Total outstanding – September 30, 2025   1,159,270   $2.72     $2.47 — $6.50     4.89 
Exercisable   1,159,270   $2.72     $2.47 — $6.50     4.89 
Non-Exercisable   —    —    —    — 

 

25

 

 

NOTE 16 — PARENT COMPANY EQUITY HELD AT COST

 

In January 2026, the Company established an entrusted investment arrangement with GKA, acting as fiduciary, to indirectly acquire equity securities of FFAI, the Company’s majority stockholder. The transaction was completed through staged agreement executions and fund contributions, with final closing occurring on April 15, 2026.

 

On January 30, 2026, the Company entered into the initial entrusted investment agreement with GKA and remitted $10.0 million in initial prepaid investment funds, which were designated for subscription to FFAI equity securities. On April 10, 2026, the parties executed an amendment to the entrusted investment agreement, pursuant to which the Company advanced an additional $2.0 million in short-term bridge funding to FFAI through GKA, with interest accruing from the advance date through closing. At the April 15, 2026 closing, the $10.0 million initial prepaid principal, the $2.0 million additional bridge principal, and $2,192 of accrued bridge loan interest were collectively applied toward the $12,002,192 aggregate subscription amount under the amended and restated securities purchase agreement, in exchange for 1,926,337 shares of FFAI Class A common stock and 11,502 shares of FFAI Series C Convertible Preferred Stock. FFAI also issued GKA a four-year stock purchase warrant (“FFAI warrant”), which entitles the registered holder to acquire up to 1,000,000 shares of Class A common stock at an exercise price of $1.50 per share. The FFAI warrant becomes exercisable only after FFAI completes delivery of its 500th FX Super One vehicle, and is subject to the stated ownership and Nasdaq issuance limitations. Management evaluated the FFAI warrant and concluded that it does not represent a separately recognizable unit of account and that no portion of the aggregate subscription price is required to be allocated to the FFAI warrant, based on the FFAI warrant is held by GKA as fiduciary on behalf of the Company as part of the entrusted investment and is an integral component of the parent-directed transaction accounted for as contra-equity.

 

As of September 30, 2026, the total carrying value of the Company’s indirect investment in shares of FFAI’s common stock and preferred stock was $12,002,192. At closing, the Company recorded the full aggregate subscription amount into parent company equity held at cost, a contra-equity account measured at historical cost and no separate accounting entry is recorded for the FFAI warrant. This accounting treatment applies uniformly to both the FFAI Class A common stock and Series C Convertible Preferred Stock, with no subsequent fair value remeasurement recognized in the condensed consolidated financial statements as of September 30, 2026.

 

NOTE 17 — RELATED PARTY TRANSACTIONS

 

Lead Investor Agreement

 

In connection with the Subscription Agreement, the Company and Faraday entered into a lead investor agreement (the “Lead Investor Agreement”), pursuant to which, Faraday committed to invest a minimum of $30 million in a private placement. The material terms of the Lead Investor Agreement include:

 

  ● Treasury Reserve & Crypto Custody: The Company will adopt a Treasury Reserve Policy establishing cryptocurrencies as its primary ongoing treasury reserve asset.  
  ● Executive Appointments: Concurrent with the closing, Faraday appointed Jiawei Wang as Co-Chief Executive Officer and Koti Meka as Chief Financial Officer. The Faraday-appointed Co-Chief Executive Officer is solely responsible for all non-legacy business operations and has been granted sole access to all crypto-related accounts of the Company, subject to delegation. On June 20, 2026, Koti Meka resigned as Chief Financial Officer, and effective June 21, 2026, Jie Sheng was appointed as President and Chief Financial Officer. Jiawei Wang continued to serve as Chief Executive Officer of the Company.
  ● Board Restructuring: The Board size was initially reduced to five members, with Faraday appointing two directors to fill vacancies. Following stockholder approval, the Board will expand to seven members, granting Faraday the right to appoint up to two additional directors. Faraday retains the right to proportional board representation so long as it maintains at least 5% beneficial ownership of the Company’s common stock.
  ● Transitional Governance Controls: Prior to receiving stockholder approval, the Faraday-appointed Co-Chief Executive Officer will manage all new business affairs and holds the exclusive authority to approve and execute new agreements on behalf of the Company. Legacy business affairs continue to be managed by the current Chief Executive Officer.

 

Actual proceeds from the Lead Investor Agreement from Faraday as well as several members of Faraday’s executive management team amounted to $34.2 million.

 

As part of the Lead Investor Agreement, Yueting Jia, the Chief Executive Officer of the Company and the Global Chief Executive Officer of Faraday, contributed $4,000,000.

 

As part of the Lead Investor Agreement, Jiawei Wang, the Company’s Executive Chairman and a director, contributed $200,000.

 

On October 12, 2026, the Company entered into an amended and restated lead investor agreement with FF Global Partners LLC (“FFGP”), FFAI, Yueting Jia and Jiawei Wang. Except for specified provisions effective upon signing, the amended agreement becomes effective upon satisfaction of its effectiveness conditions, including consummation of the robotics acquisition. See Note 19 — Subsequent Events.

 

26

 

 

Transition Services Agreement

 

On September 30, 2025, the Company entered into a transition services agreement with FFAI, under which FFAI provides support and management services to the Company. During the nine months ended September 30, 2026, the Company recognized service fees of approximately $553,000, respectively, under the agreement. At September 30, 2026, prepaid service fees of $370,055 were included in other assets — related party. At December 31, 2025, approximately $1.0 million of unpaid service fees was included in related party payable.

 

Master Services Agreement

 

On June 3, 2026, the Company entered into a master services agreement (“MSA”) with FFAI under which the Company provides consulting, advisory, operational, capital markets, technical, legal and other support services pursuant to separately executed statements of work. The MSA has an initial term of one year and automatically renews for successive one-year periods unless terminated in accordance with its terms. Compensation is determined under individual statements of work and generally consists of reimbursement of direct personnel costs, allocated overhead, an 18% service fee and certain direct expenses. The Company recognized no revenue under the MSA during the three and nine months ended September 30, 2026.

 

Related-Party Advances to FFAI

 

During the nine months ended September 30, 2026, the Company advanced an aggregate of $1,850,000 to FFAI, the Company’s majority stockholder, beginning with an initial advance of $250,000 funded on July 20, 2026. The advances were authorized by a special committee of the Board of the Company, composed solely of directors determined to be independent of, and disinterested with respect to, FFAI. The advances bear interest at 10% per annum, with a default rate of 15% per annum, are unsecured, and rank pari passu with FFAI’s other unsecured and unsubordinated indebtedness. The proceeds of each advance were restricted to a purpose specified at the time of that advance. The initial advance was restricted to funding a payment in connection with a sponsorship arrangement involving an affiliate of FFAI, and the subsequent advances were restricted to FFAI’s operating costs.

 

At September 30, 2026, outstanding principal and accrued interest totalled $1,866,096, consisting of $1,850,000 of principal and $16,096 of accrued interest. The Company recognized interest income of $16,096 during both the three and nine months ended September 30, 2026. These amounts were included in short-term related party notes receivable in the unaudited condensed consolidated balance sheet.

 

The advances are documented by an uncommitted, non-revolving delayed draw credit facility providing for aggregate advances of up to $2.0 million, under which the Company has no obligation to make any advance. Amounts advanced to FFAI are not available to fund the Company’s operations, and their repayment depends on FFAI’s financial condition. See Note 19 - Subsequent Events.

 

Consulting Agreement with Aibot

 

On July 29, 2026, the Company entered into a consulting agreement with Aibot, effective July 16, 2026, under which Aibot provides finance, capital markets and human resources/legal coordination support services. The agreement continues through July 15, 2027, unless extended or terminated earlier in accordance with its terms, and provides for monthly consulting fees of $50,000 and reimbursement of certain approved expenses. Aibot is minority owned by Jiawei Wang, the Company’s Executive Chairman and a director, who also serves on Aibot’s board of directors. The agreement was reviewed and approved by the disinterested members of the Company’s Board and its Audit Committee.

 

During the three months ended September 30, 2026, the Company paid Aibot $250,000, including advance payments of $125,000. The Company recognized consulting expenses of $125,000 under the agreement during both the three and nine months ended September 30, 2026. At September 30, 2026, prepaid consulting fees of $125,000 were included in other assets — related party.

 

Related Party Accrued Expenses

 

On October 2, 2025, the Company entered into an advisory agreement with Yueting Jia, a related party and significant stockholder, pursuant to which Yueting Jia serves as Chief Advisor. The agreement provides an annual advisory fee of $500,000, a target annual performance fee of $500,000, a one-time engagement fee of $300,000, and potential annual equity awards, subject to board approval and vesting conditions. The agreement has an initial term of three years. During the three and nine months ended September 30, 2026, the Company recognized advisory service expenses under this agreement of $200,001and $600,003, respectively, and had related-party payables of $191,667 as of September 30, 2026.

 

On January 28, 2026, the Company entered into a consulting services agreement with FF Global Partners LLC, a related party (“FF Global”), effective as of November 1, 2025, under which FF Global provides strategic planning, capital markets advisory, blockchain and technology consulting, and operational support services. The agreement expires on December 31, 2026 and provides for a monthly consulting fee of $100,000, performance-based bonuses at the discretion of the Company’s management and Board, and reimbursement of certain approved business expenses. During the three and nine months ended September 30, 2026, the Company recorded related-party consulting expenses of $300,000 and $900,000, respectively. As of September 30, 2026, $100,000 was outstanding and was classified under related party payable.

 

At September 30, 2026, accrued director fees totalled $25,625 and were included in related party payable.

 

27

 

 

Parent Equity Held at Cost

 

During the nine months ended September 30, 2026, the Company invested an aggregate of approximately $12.0 million in FFAI through GKA. Upon closing on April 15, 2026, the aggregate subscription amount, including accrued interest, was converted into FFAI Class A common stock and Series C Convertible Preferred Stock. The Company recorded the full aggregate subscription amount of $12.0 million as parent company equity held at cost, which remained the carrying value of the investment as of September 30, 2026. See Note 16 for further details regarding the investment transaction and related accounting treatment.

 

Related-Party Robotics Acquisition

 

On September 25, 2026, the Company entered into a non-binding term sheet with FFAI regarding a proposed acquisition of FFAI’s robotics business for an indicative transaction value of approximately $200 million. The term sheet did not create a binding obligation to consummate the acquisition. On October 12, 2026, the Company entered into a definitive transaction agreement with FFAI, Smart Technology Holdings Ltd., a subsidiary of FFAI, FF EAI Robotics Inc. (“RobotCo”) and FFR Acquisition Sub LLC (“Merger Sub”), a wholly owned subsidiary of the Company. On October 23, 2026, the Company completed the acquisition of all issued and outstanding shares of RobotCo from Smart Technology Holdings Ltd. Immediately thereafter, RobotCo merged with and into Merger Sub, with Merger Sub surviving as a wholly owned subsidiary of the Company. At closing, the Company issued 1,315,313 shares of common stock and 65,475 shares of Series C Non-Voting Convertible Preferred Stock to Smart Technology Holdings Ltd. as consideration and assumed the outstanding RobotCo stock options. The contractual consideration was determined using a $200.0 million valuation base, adjusted to exclude the portion attributable to outstanding RobotCo options, and a consideration share price of $2.246. See Note 19 — Subsequent Events.

 

Warrants

 

On May 22, 2020, as a commitment fee, the Company issued warrants to Alpha for the purchase of common stock. As of December 31, 2024, 141 of these warrants remained outstanding and exercisable, and were able to be exercised in whole or in part, at any time before May 22, 2025. These warrants expired, and as of December 31, 2025, none of these warrants remain outstanding and exercisable. During years ended December 31, 2025 and 2024 there were no exercises of those warrants. The warrants were equity classified as of December 31, 2023 and were reclassified to warrant liabilities during the year ended December 31, 2024 (see Note 9 - Warrant Liabilities).

 

On December 22, 2022, in conjunction with the issuance of a debenture to Alpha (the “2022 Alpha Debenture”), the Company issued to Alpha a warrant to purchase 50,000 shares of the Company’s common stock. This warrant may be exercised by Alpha, in whole or in part, on or after June 22, 2023 and at any time before June 22, 2028, subject to certain terms and conditions described in the warrant. During the year ended December 31, 2024, Alpha partially exercised this warrant to purchase 31,998 shares respectively, of the Company’s common stock at a weighted average exercise price of $13.00, for total cumulative proceeds to the Company of $416,000. During the year ended December 31, 2025, there were no exercises of this warrant. This warrant is included in equity on the Company’s unaudited condensed consolidated balance sheets (see Note 15 – Stockholders’ Equity ).

 

On February 27, 2024, in conjunction with the issuance of a debenture to Alpha (the “2024 Alpha Debenture”), the Company issued to Alpha, the 2024 Alpha Warrant to purchase 18,001 shares of the Company’s common stock, exercisable in whole or in part, until February 27, 2029, subject to certain terms and conditions described in the warrant. The 2024 Alpha Warrant is presented on the balance sheet as an equity classified warrant.

 

On September 6, 2024, as a result of the down-round provision triggered by shares sold in a public offering, the above warrants were repriced from $13.00 per share exercise price to $6.50 per share exercise price. The Company recognized an additional deemed dividend of $27,587, which represents the incremental fair value of the outstanding warrants as a result of the down-round provision. As the Company has an accumulated deficit, the deemed dividend was recorded as a reduction in additional paid-in capital, resulting in a net impact of zero to additional paid-in capital in the unaudited condensed consolidated statements of changes in stockholders’ equity. On April 28, 2025, as a result of the down-round provision triggered by the issuance of the 2025 Convertible Note, the warrant was repriced from an exercise price of $6.50 per share to an exercise price of $5.82 per share. No further down-round provisions were triggered by the July 28, 2025 private placement transaction or the Subscription Agreement as these warrants were at their contractual floor.

 

As a result of a partial voluntary conversion of the 2024 Alpha Debenture on September 9, 2024, the Company no longer had sufficient shares to settle the 2024 Alpha Warrant in full until stockholder approval was obtained, and a portion (2,314 warrant shares with a fair value of $14,997) was reclassified to liabilities (see Note 9 – Warrant Liabilities). Stockholder approval was subsequently obtained on October 25, 2024, and as of that date, the Company determined that stockholder approval resulted in equity classification for the warrant again and, accordingly, the Company remeasured the warrant liability to fair value, and reclassified to noncompensatory equity classified warrants.

 

During the nine months ended September 30, 2026, there were no exercises of this warrant. This warrant is included in equity on the Company’s unaudited consolidated balance sheets (see Note 15 – Stockholders’ Equity).

 

As of September 30, 2026, the exercise price of the 2022 Alpha Warrant was $6.50 per share, while the exercise price of the 2024 Alpha Warrant was $5.82 per share.

 

On April 12, 2024, in connection with the issuance of a debenture to Yi Hua Chen (see Note 10 – Convertible Debt), the Company issued a liability classified warrant to Yi Hua Chen to purchase 36,001 shares of common stock, exercisable until February 27, 2029. On September 6, 2024, as a result of a down-round provision triggered by shares sold in a public offering, the warrant was repriced from an exercise price of $13.00 per share to an exercise price of $6.50 per share. The warrant was initially liability classified due to an insufficient number of authorized shares to settle the warrant prior to the receipt of stockholder approval, which was subsequently obtained on October 25, 2024. As of that date, the Company determined that stockholder approval resulted in equity classification for the warrant and accordingly, the Company remeasured the warrant liability to fair value, and reclassified to noncompensatory equity classified warrants (see Note 15 – Stockholders’ Equity). The fair value of this warrant was $565,582 on the issuance date and $185,531 on the date of reclassification to equity. On April 28, 2025, as a result of the down-round provision triggered by the issuance of the 2025 Convertible Note, the warrant was repriced from an exercise price of $6.50 per share to an exercise price of $5.82 per share. No further down-round provisions were triggered by the July 28, 2025 private placement transaction or the Subscription Agreement as these warrants were at their contractual floor.

 

NOTE 18 — SEGMENT INFORMATION

 

The Company operates as a single operating and reportable segment. This determination is consistent with the manner in which the Company’s Chief Operating Decision Maker (“CODM”) evaluates performance, allocates resources, and reviews financial results.

 

The CODM consists of the Company’s Chief Executive Officer and its Chief Financial Officer. The CODM reviews consolidated financial information and does not receive discrete financial information for separate business components.

 

In accordance with ASC 280, Segment Reporting, the Company has concluded that it has one operating and reportable segment because its financial results are reviewed on a consolidated basis and no component meets the definition of a separate operating segment.

 

The Company’s single reportable segment includes RoboShare platform and operating services, software development and remaining legacy activities. Its strategic focus is transitioning toward embodied AI robotics.

 

28

 

 

On May 21, 2026, the Board approved the permanent discontinuation of the Company’s legacy biotechnology business. Before approving the wind-down plan, management evaluated strategic alternatives, including a potential sale of the business and related intellectual property, and determined that an orderly wind-down was in the best interests of the Company and its stockholders. By September 30, 2026, the Company had completed the wind-down and no longer held operating assets associated with the legacy biotechnology business. No additional wind-down expenses were incurred during the three months ended September 30, 2026. The historical operating results and related expenses of the legacy biotechnology business are included in continuing operations within the Company’s single reportable segment.

 

The CODM evaluates performance and allocates resources based on consolidated net loss. The CODM reviews the Company’s significant segment expenses, which are its consolidated operating expenses, including research and development, general and administrative, and interest and other expenses, broken out as follows:

 

   2026   2025   2026   2025 
  

For the Three Months Ended

September 30,

  

For the Nine Months Ended

 September 30,

 
   2026   2025   2026   2025 
                 
Revenue  $4,473    —   $4,473    — 
Cost of revenue   14,114    —    14,114      
Gross loss   (9,641)   —    (9,641)   — 
EXPENSES                    
General and administrative   4,282,759    1,891,108    10,699,149    5,780,572 
Sales and marketing   20,000    —    743,937    — 
Research and development   —    105,576    10,146    156,558 
Credit loss expense - short-term note receivable   —    (567,000)   142,574    (99,000)
Total expenses   4,302,759    1,429,684    11,595,806    5,838,130 
Net (gain) loss on digital assets   (1,679,390)   —    1,250,556    — 
Other expense (income), net   93,124    608,135    136,752    531,242 
Total other expense (income), net   (1,586,266)   608,135    1,387,308    531,242 
Income taxes   —    —    —    35 
NET LOSS   (2,726,134)   (2,037,819)   (12,992,755)   (6,369,407)

 

The CODM evaluates the Company’s financial position based on the consolidated balance sheet and does not review segment-level asset information. Accordingly, no separate segment asset disclosures are presented.

 

NOTE 19 — SUBSEQUENT EVENTS

 

The Company has evaluated subsequent events through the date these financial statements were available to be issued. The Company is not aware of any other events requiring recognition or disclosure in these financial statements.

 

In early October 2026, the Company collected in full the $2,039 ELOC subscription receivable outstanding at September 30, 2026. Subsequent to September 30, 2026, the Company also sold an additional 319,706 shares of common stock under the ELOC for aggregate gross proceeds of $571,257. The net proceeds were $461,254, of which $461,254 was received in cash through the date these unaudited condensed consolidated financial statements were issued. As of that date, 3,712,269 shares remained delivered in advance of future purchases. On November 15, 2026, the Company and GKA entered into a letter agreement, effective as of September 14, 2026, the date the Company’s registration statement on Form S-1 (File No. 333-297725) was declared effective, confirming the terms on which GKA has held shares delivered to it in advance of settlement since that date. Under the letter agreement, the Company retains all beneficial interest in the pre-delivered shares; GKA has paid no consideration for them, has waived any right to vote them or to receive dividends or other distributions in respect of them, and may not sell, transfer or pledge them except in settlement of a VWAP purchase for which the Company has delivered a purchase notice; and the Company may require their return at any time without payment of consideration. See Notes 12 and 15.

 

On October 12, 2026, the Company entered into a definitive transaction agreement with FFAI, Smart Technology Holdings Ltd., RobotCo and Merger Sub. The agreement used a $200.0 million valuation base, adjusted to exclude the portion attributable to outstanding RobotCo options and a consideration share price of $2.246. The Company’s Board approved the transaction following the recommendation of its independent special committee and receipt of a fairness opinion. On October 23, 2026, the Company completed the acquisition of all outstanding shares of RobotCo from Smart Technology Holdings Ltd. Immediately thereafter, RobotCo merged with and into Merger Sub, with Merger Sub surviving as a wholly owned subsidiary of the Company. At closing, the Company issued 1,315,313 shares of common stock and 65,475 shares of Series C Non-Voting Convertible Preferred Stock as consideration. The Company also assumed outstanding RobotCo options, which were converted into options to acquire the Company’s common stock using an exchange ratio of 0.89. The acquisition did not itself provide cash proceeds to the Company. Upon the closing of the acquisition, a transaction fee became payable to Curvature Securities, LLC, the Company’s financial advisor for the acquisition. The fee was contingent on the closing and was not accrued at September 30, 2026. The Company intends to settle the fee by issuing 445,236 shares of Series C-1 Non-Voting Convertible Preferred Stock upon filing of the related certificate of designation.

 

In connection with the acquisition, the Company and the applicable subsidiaries entered into intellectual property assignment and royalty-free technology licensing arrangements with FFAI and its affiliates for the robotics business. The seller parties also became subject to an 18-month lock-up covering the consideration securities, subject to specified exceptions. The Company, FFAI and RobotCo also entered into a transition services agreement effective October 1, 2026. Under the agreement, FFAI provides services supporting the robotics business, including EAI devices, the EAI brain and developer platform, data factory and industry solutions. Fees equal FFAI’s actual, direct and documented costs, without markup. The initial term is twelve months and may be extended by mutual agreement. This agreement is separate from the transition services agreement entered into in September 2025.

 

Also in connection with the acquisition and as described in Note 17, on October 12, 2026, the Company entered into an amended and restated lead investor agreement with FFGP, FFAI, Yueting Jia and Jiawei Wang. Upon consummation of the robotics acquisition on October 23, 2026, the conditions to effectiveness of the amended agreement were satisfied, and the amended agreement became effective and superseded the original Lead Investor Agreement. The amended agreement is described in the Company’s Current Report on Form 8-K filed with the SEC on October 14, 2026.

 

Effective upon the closing of the acquisition on October 23, 2026, Yueting Jia was appointed Chief Executive Officer and his advisor agreement with the Company was terminated, and Jiawei Wang ceased to serve as Chief Executive Officer and was appointed Executive Chairman, as previously disclosed in the Company’s Current Report on Form 8-K filed with the SEC on October 26, 2026. On November 13, 2026, Jie Sheng resigned as President of the Company. He continues to serve as Chief Financial Officer and as a director.

 

On October 12, 2026, the Company entered into a securities purchase agreement with certain investors for a private placement of common stock and, where applicable under the beneficial ownership limitation, Series D non-voting convertible preferred stock for aggregate gross proceeds of up to $10.0 million. The subscription price for the common stock is $1.50 per share. The agreement has no minimum aggregate funding condition. Securities are issued against receipt of the applicable subscription proceeds. Net proceeds are designated for the development and operations of the Company’s robotics business. As of the date the Company has received $300,000 under the PIPE from one investor, whose purchase of Series D Preferred Stock will close upon effectiveness of the related certificate of designation. The Company may sell additional securities under the PIPE, but no other investor is currently committed to purchase, and there can be no assurance that any additional amount will be funded.

 

In October 2026, the Company advanced an additional $150,000 to FFAI, bringing aggregate advances to FFAI to $2,000,000, all of which remains outstanding. On November 10, 2026, the Company and FFAI entered into a credit facility agreement, effective as of July 20, 2026, documenting the advances. The agreement provides for advances of up to $2,000,000 in the aggregate on an uncommitted, non-revolving basis, bears interest at 10% per annum with a default rate of 15% per annum, is unsecured, ranks pari passu with FFAI’s other unsecured and unsubordinated indebtedness, and matures July 20, 2027. The agreement was approved by a special committee of the Board composed solely of independent and disinterested directors. See Note 17 - Related Party Transactions.

 

On November 12, 2026, the Board ratified, under Section 204 of the Delaware General Corporation Law (“DGCL”), the issuance of 60,257 shares of common stock on or about September 29, 2025 that had not been approved by the Board as required by Sections 152, 153 and 157 of the DGCL. Any claim challenging the ratified issuance or the ratification must be brought within 120 days after the later of the validation effective time and the date notice of the ratification is given. See Part II, Item 5.

 

29

 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

The following discussion and analysis should be read in conjunction with our interim unaudited condensed consolidated financial statements and related notes included in this Quarterly Report on Form 10-Q (this “Quarterly Report”) and the audited financial statements and notes thereto as of and for the twelve months ended December 31, 2025, which are contained in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 30, 2026, as amended on July 16, 2026. As used in this Quarterly Report, unless the context suggests otherwise, “we,” “us,” “our,” the “Company” or “FFR” refer to FF EAI Robotics Ecosystem Inc. In addition to historical information, this discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions.

 

Cautionary Note Regarding Forward Looking Statements 

 

This Quarterly Report contains forward-looking statements by the Company that involve risks and uncertainties and reflect the Company’s judgment as of the date of this Report. These statements generally relate to future events or the Company’s future financial or operating performance. In some cases, you can identify forward-looking statements because they contain words such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” or “continue” or the negative of these words or other similar terms or expressions that concern the Company’s expectations, strategy, plans or intentions. Such forward-looking statements may relate to, among other things, potential future development, testing and launch of products and services, the acquisition of FFAI’s robotics business and related financings. Actual events or results may differ from our expectations due to a number of factors.

 

Some of the factors that we believe could cause actual results to differ from those anticipated or predicted include:

 

  ● the timing, method, price and effects of the orderly disposition of any remaining digital-asset positions following our exit from our digital-asset treasury strategy;
  ● our ability to integrate and operate the robotics business if acquired, the risk that it performs differently than anticipated, and our dependence on FFAI for transition, supply and support following any closing;
  ● our ability to complete the PIPE and any other financing on the anticipated terms, in the anticipated amounts or at all;
  ● the regulatory landscape applicable to RoboShare, robotic equipment rentals and services, autonomous or unmanned systems, transportation, data protection, tax and safety, including restrictions on foreign-produced robotic devices;
  ● our ability to operate and scale RoboShare’s asset-light marketplace and related rental and service offerings, including customer adoption, repeat demand, utilization and expansion beyond Los Angeles, the development, commercialization, and market acceptance of our current and future products and services;
  ● our reliance on third-party robot owners, merchants, service providers, logistics providers and strategic relationships, including key commercial counterparties;
  ● expansion into new markets, jurisdictions, and operating modalities, including autonomous or unmanned systems, and receipt of necessary regulatory approvals;
  ● competitive conditions, customer demand, and pricing trends affecting our products and services;
  ● our ability to design, launch, and enhance products and services that meet customer needs on a timely basis;
  ● the performance of counterparties and our exposure to contractual and commercial risks;
  ● the stability, security, and performance of our technology systems, infrastructure, and networks, including cybersecurity risks;
  ● our ability to attract, retain, and incentivize qualified personnel and manage growth effectively;
  ● our ability to obtain additional financing or capital when needed and on acceptable terms, including our ability to access the equity line of credit subject to its conditions, the exchange cap and required stockholder approvals;
  ● litigation exposure and the potential impact of legal or regulatory proceedings;
  ● protection and enforcement of our intellectual property and defense against third-party claims;
  ● the ability to maintain the listing of our common stock on Nasdaq;
  ● our dependence on our relationship with Faraday Future Intelligent Electric Inc. (“FFAI”), our majority stockholder, including transactions with it and its affiliates, our advances to FFAI and the related concentration and conflict-of-interest risks;
  ● our dependence on Gold King Arthur Holding Limited’s (“GKA’s) performance of its obligations under the entrusted investment agreement, under which our investment in FFAI securities is held indirectly on our behalf;
  ● material weaknesses in our internal control over financial reporting and our ability to remediate them;
  ● substantial doubt about our ability to continue as a going concern; and
  ● recent transitions in our executive officers and the composition of our board of directors and audit committee, and our ability to effect an orderly transition.

 

By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics and depend on the economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. Although we believe that we have a reasonable basis for each forward-looking statement contained in this Quarterly Report, we caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this Quarterly Report. In addition, even if our results of operations, financial condition and liquidity, and the development of the industry in which we operate, are consistent in some future periods with the forward-looking statements contained in this Quarterly Report, they may not be predictive of results or developments in other future periods. Any forward-looking statement that we make in this Quarterly Report speaks only as of the date of this Quarterly Report, and we disclaim any intent or obligation to update these forward-looking statements beyond the date of this Quarterly Report, except as required by law. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

 

Future filings with the SEC, future press releases and future oral or written statements made by us or with our approval, which are not statements of historical fact, may also contain forward-looking statements. Because such statements include risks and uncertainties, many of which are beyond our control, actual results may differ materially from those expressed or implied by such forward-looking statements. The forward-looking statements speak only as of the date on which they are made, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they are made.

 

30

 

 

Overview 

 

We are a physical AI and embodied artificial intelligence (“EAI”) robotics company, building a U.S.-based robotics ecosystem, whose principal near-term operating and commercialization priority is RoboShare, an on-demand robot-sharing and matchmaking marketplace. RoboShare connects robot owners with enterprises, educational institutions and other users seeking flexible access to robotic equipment and related services, including whole-machine rentals and service-based usage. In the third quarter of 2026, we took significant steps to focus on robotics. In August 2026, we announced a strategic shift toward robotics operations and commercialization, including an orderly exit from our digital-asset treasury strategy. In October 2026, we closed a related-party acquisition of the robotics business of FFAI, our majority stockholder, and began transition toward a platform-based physical AI robotics ecosystem. Through this acquisition, we expect to add FFAI’s multi-form EAI robotics product lines, EAI Brain and developer platform capabilities and education, industrial and security applications to our business, and to create opportunities across robot sales, leasing, deployment and recurring services through RoboShare. In connection with the acquisition, we also entered into a securities purchase agreement for a private placement of up to $10.0 million (the “PIPE”), the net proceeds of which are intended to fund the development and operations of our robotics business. We expect to receive $300,000 under the PIPE shortly after the date of this Quarterly Report, and there can be no assurance that any additional amounts will be funded. Conversion of the preferred stock issued as consideration in the acquisition will require stockholder approval. In September 2025, we completed an approximately $41 million PIPE financing and subsequently changed our name from Qualigen Therapeutics to AIxCrypto Holdings, Inc. To reflect our robotics focus, effective September 30, 2026, our legal name became FF EAI Robotics Ecosystem Inc. and our Nasdaq ticker became “FFR.” During the three months ended September 30, 2026, RoboShare began commercial operations and generated our first revenue. Consistent with our robotics focus, we substantially completed our exit from the digital-asset treasury strategy and held no material digital assets as of September 30, 2026.

 

On May 21, 2026, our board of directors approved the permanent discontinuation and orderly wind-down of our legacy biotechnology business. By September 30, 2026, we had completed the wind-down, and no operating assets associated with the legacy biotechnology business remained. We incurred no additional wind-down costs during the three months ended September 30, 2026. See Note 14 — Research and License Agreements and Note 18 — Segment Information of our financial statements in this Quarterly Report for additional information.

 

Core Operating Focus

 

Physical AI and RoboShare

 

RoboShare connects third-party providers of robotic services with customers and also offers optional operating, transportation, setup and production services. We launched the platform publicly on June 22, 2026. Management prioritized RoboShare after observing customer demand and willingness to pay for access to robotic equipment and services. Los Angeles is RoboShare’s primary operating market and the first market activation under our planned ten-city direction. As of September 1, 2026, 82 robots were listed on the platform. We received our first paid order on August 15, 2026 and delivered our first commercial event on August 27, 2026. Under our asset-light marketplace model, third-party owners list robots on the platform, and we do not own any robot equipment. We earn platform fees, recognized net as an agent, and gross fees for operating services we control as principal, and customers generally prepay before service. Providers retain ownership of their robots, including equipment provided by FFAI, a related party. We recognized our first revenue of $4,473 in the three months ended September 30, 2026. As an early-stage platform, our initial bookings are not yet indicative of recurring demand.

 

We intend to grow RoboShare by expanding our robot-owner and customer network, broadening the services we offer, automating scheduling, dispatch, merchant onboarding and payment processes that are currently performed manually, and entering additional markets based on operating results. Our ability to do so depends on attracting reliable providers and customers, completing bookings, delivering safe services and collecting fees, and future booking volume, margins and cash generation remain uncertain. If completed, the proposed acquisition would broaden our product and service offering; however, the robotics business’s sales, assets and forecasts are not part of our reported results of operations for the three and nine months ended September 30, 2026.

 

Real-World Asset (“RWA”) Tokenization

 

RWA tokenization and related software initiatives have not generated material revenue and, together with our EAI infrastructure and AIxC Hub initiatives, are currently deprioritized as we focus on robotics. In connection with the robotics transaction, we commenced a planned strategic exit from cryptocurrency activities.

 

Following the completion of the transaction, the Company commenced the following lines of business:

 

Physical AI Device

 

Our Physical AI Devices business covers humanoid robots, bionic robots and other intelligent robotic products for use in education and research, security and inspection, industrial and logistics, commercial and service settings. Through the commercialization of robotic products, hardware integration and related services, we aim to drive market adoption and scaled deployment of our robotic devices.

 

Physical AI Brain & Developer Platform

 

Our Physical AI Brain & Developer Platform develops and integrates intelligent capabilities for robots, including decision-making, perception, interaction, motion control and task execution. We are building an AI capability platform designed to work across different robot form factors. Through developer tools and an open ecosystem, the platform is intended to support continuous upgrades of robotic intelligence and the expansion of its applications.

 

Industry Productivity Solutions

 

Our Industry Productivity Solutions business serves customers in education and research, industrial and logistics, security and inspection, commercial and services. It provides integrated solutions that combine robotic hardware, AI capabilities and application-specific deployments. The goal is to move robotics from product delivery to measurable productivity in real-world operations. We are also exploring revenue opportunities in systems integration, technical services and recurring services.

 

Physical AI Data Factory

 

Our Physical AI Data Factory is building capabilities to collect, process, label, manage and apply data generated during robot training, deployment and real-world operation. These capabilities are intended to support the training, optimization and iteration of our robotic intelligence models. We are also exploring opportunities to commercialize data services and related offerings.

 

31

 

 

Recent Developments

 

Marizyme

 

On May 12, 2026, the Company entered into a note purchase agreement to assign all outstanding Marizyme, Inc. (“Marizyme”) loan and creditor claims. On May 14, 2026, the Marizyme notes, with a gross balance of approximately $5.2 million including accrued interest and a net carrying value of $475,844 after credit-loss allowances, were extinguished for $100,000 in cash. The Company recorded a $375,844 loss on settlement for the nine months ended September 30, 2026. The note receivable and related allowance were removed from the balance sheet, eliminating the Company’s remaining Marizyme note exposure. The assignment did not modify the Company’s contingent royalty rights under its co-development agreement with Marizyme, dated April 11, 2024, and no royalty receivable was recorded as of September 30, 2026.

 

Faraday Investment

 

Pursuant to amended investment documents executed on April 10 and April 14, 2026, the aggregate investment consideration for the Company’s FFAI securities position was increased to $12,002,192, and the transaction closed on April 15, 2026. At closing, GKA received 1,926,337 shares of FFAI Class A common stock, 11,502 shares of FFAI Series C Convertible Preferred Stock and a four-year warrant to purchase up to 1,000,000 shares of FFAI Class A common stock on the Company’s behalf. The securities held indirectly through GKA were classified as parent company equity held at cost within stockholders’ equity as of June 30, 2026. The position is intended to serve as a proof-of-concept asset for the Company’s RWA tokenization strategy; partial tokenization remains subject to technical and regulatory evaluation and had not been executed as of September 30, 2026.

 

Critical Accounting Policies and Estimates

 

This discussion and analysis is based on our unaudited condensed consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these unaudited condensed consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our unaudited condensed consolidated financial statements. An accounting policy is deemed to be critical if it requires an accounting estimate to be made based on assumptions about matters that are highly uncertain at the time the estimate is made, and if different estimates that reasonably could have been used, or changes in the accounting estimates that are reasonably likely to occur periodically, could materially impact the unaudited condensed consolidated financial statements. While the Company’s significant accounting policies and estimates are further outlined in Note 1 - Business and Summary of Significant Accounting Policies and Estimates of the unaudited condensed consolidated financial statements, management considers the accounting for digital assets at fair value, the valuation of warrant liabilities and ELOC purchase commitments, RoboShare revenue recognition and the going concern assessment to be critical accounting estimates. These areas involve significant judgments and assumptions about inherently uncertain matters, and changes in these estimates could materially impact the Company’s condensed consolidated financial position and results of operations.

 

32

 

 

Results of Operations

 

Comparison of the three months ended September 30, 2026 and 2025:

 

   For the Three Months Ended September 30, 
   2026   2025 
         
Revenue  $4,473    — 
Cost of revenue   14,114    — 
Gross loss   (9,641)   — 
           
EXPENSES          
General and administrative   4,282,759    1,891,108 
Sales and marketing   20,000    — 
Research and development   —    105,576 
Credit loss expense - short-term note receivable   —    (567,000)
Total expenses   4,302,759    1,429,684 
           
LOSS FROM OPERATIONS   (4,312,400)   (1,429,684)
           
OTHER EXPENSE (INCOME), NET          
Loss on change in fair value of warrant liabilities   7,371    148,346 
Loss on change in fair value of convertible debt   —    197,667 
Interest expense   —    455,941 
Interest income   (18,162)   (193,819)
Loss on ELOC facility   3,915    — 
ELOC commitment fee   100,000    — 
Net (gain) loss on digital assets   (1,679,390)   — 
Total other expense (income), net   (1,586,266)   608,135 
           
LOSS BEFORE PROVISION FOR INCOME TAXES   (2,726,134)   (2,037,819)
           
PROVISION FOR INCOME TAXES   —    — 
           
NET LOSS   (2,726,134)   (2,037,819)
           
Deemed dividend arising from warrant down-round provision   

-

    

(867,796

)
           
Total net loss per share of common stock, basic and diluted  $(0.13)  $(4.68)
Weighted-average number of shares outstanding basic and diluted   20,787,933    620,694 

 

33

 

 

Revenue

 

Revenue increased from nil for the three months ended September 30, 2025 to $4,473 for the three months ended September 30, 2026. The increase resulted from the commencement of commercial activities through our RoboShare platform during the third quarter of 2026, including robot operating and production services and net marketplace commissions.

 

Cost of Revenue and Gross Loss

 

Cost of revenue increased from nil for the three months ended September 30, 2025 to $14,114 for the three months ended September 30, 2026. The increase resulted from amortization of capitalized software placed in service in July 2026. We recorded a gross loss of $9,641 for the 2026 period, compared with nil for the corresponding 2025 period, as software amortization exceeded the $4,473 of revenue generated from RoboShare’s initial commercial activities.

 

Expenses

 

General and Administrative Expenses

 

General and administrative expenses increased by $2.4 million, or 126%, from $1,891,108 for the three months ended September 30, 2025 to $4,282,759 for the three months ended September 30, 2026. The increase was primarily attributable to $2.0 million of noncash consulting expense recognized in connection with shares of common stock issued to a consultant in September 2026, representing approximately 84% of the increase. The remaining net increase of $391,145 related to other general and administrative costs supporting our technology and robotics business activities and public company operations.

 

Sales and Marketing Costs

 

Sales and marketing expenses increased from nil for the three months ended September 30, 2025 to $20,000 for the three months ended September 30, 2026. The increase consisted of advertising expenses associated with our commercialization activities.

 

Research and Development Costs

 

Research and development expenses decreased from $105,576 for the three months ended September 30, 2025 to nil for the corresponding 2026 period following cessation of our legacy biotechnology development activities. We completed the wind-down by September 30, 2026 and incurred no additional wind-down costs during the quarter.

 

Credit Loss Expense – Short-Term Note Receivable

 

Credit loss expense on short-term notes receivable was nil for the three months ended September 30, 2026, compared with a $567,000 reversal of the Marizyme expected credit loss allowance in the corresponding 2025 period. The Marizyme notes were settled and extinguished on May 14, 2026.

 

Other Expense (Income), Net

 

Loss on Change in Fair Value of Warrant Liabilities

 

Loss on change in fair value of warrant liabilities decreased by $140,975, or 95%, from $148,346 for the three months ended September 30, 2025 to $7,371 for the corresponding 2026 period. The decrease primarily reflected a smaller increase in our common stock price during the quarter ended September 30, 2026.

 

Loss on Change in Fair Value of Convertible Debt

 

Loss on change in fair value of convertible debt decreased from $197,667 for the three months ended September 30, 2025 to nil for the corresponding 2026 period. We repaid the remaining convertible debt in January 2026, and none remained outstanding during the third quarter.

 

Interest Expense

 

Interest expense decreased from $455,941 for the three months ended September 30, 2025 to nil for the corresponding 2026 period following repayment of our legacy debt obligations. The 2025 expense primarily reflected interest and amortization of penalties on promissory notes.

 

Interest Income

 

Interest income decreased by $175,657, or 91%, from $193,819 for the three months ended September 30, 2025 to $18,162 for the corresponding 2026 period, primarily due to settlement of the Marizyme notes in May 2026. The 2026 income consisted of $16,096 on advances to FFAI and $2,066 of dividends on cash sweep balances.

 

Loss on ELOC Facility and ELOC Commitment Fee

 

During the three months ended September 30, 2026, we recognized a $100,000 ELOC commitment fee and $3,915 of losses on ELOC forward contracts, compared with nil for both items in the corresponding 2025 period. The commitment fee related to our equity purchase facility with GKA. The forward contract losses reflected the difference between the fair value of the shares issued and the contractual net proceeds for the completed purchases, including the effect of draw fees.

 

Net Gain on Digital Assets

 

We recognized a net gain on digital assets of $1,679,390 for the three months ended September 30, 2026, compared with nil for the three months ended September 30, 2025. The gain reflected approximately $5.2 million of reversals of previously recognized unrealized losses on assets disposed of, partly offset by approximately $3.5 million of realized losses. Sales of digital assets generated approximately $6.9 million of cash proceeds during the quarter, and substantially all of our digital assets had been disposed of by September 30, 2026. We did not hold digital assets during the corresponding period in 2025.

 

34

 

 

Comparison of the Nine Months Ended September 30, 2026 and 2025:

 

  

For the Nine Months Ended

September 30,

 
   2026   2025 
         
Revenue  $4,473    — 
Cost of revenue   14,114    — 
Gross loss   (9,641)   — 
           
EXPENSES          
General and administrative   10,699,149    5,780,572 
Sales and marketing   743,937    — 
Research and development   10,146    156,558 
Credit loss expense - short-term note receivable   142,574    (99,000)
Total expenses   11,595,806    5,838,130 
           
LOSS FROM OPERATIONS   (11,605,447)   (5,838,130)
           
OTHER EXPENSE (INCOME), NET          
(Gain) loss on change in fair value of warrant liabilities   (67,255)   93,148 
(Gain) loss on change in fair value of convertible debt   (10,236)   159,793 
Loss on settlement of short-term note receivable   375,844    — 
Impairment of intangible assets   182,619    — 
Interest expense   —    635,607 
Interest income   (448,135)   (449,249)
Loss on issuance of convertible debt   —    91,943 
Loss on ELOC facility   3,915    — 
ELOC commitment fee   100,000    — 
Net (gain) loss on digital assets   1,250,556    — 
Total other expense (income), net   1,387,308    531,242 
           
LOSS BEFORE PROVISION FOR INCOME TAXES   (12,992,755)   (6,369,372)
           
PROVISION FOR INCOME TAXES   —    35 
           
NET LOSS   (12,992,755)   (6,369,407)
           
Deemed dividend arising from warrant down-round provision   

-

    

(869,382

)
           
Total net loss per share of common stock, basic and diluted  $(0.80)  $(4.35)
Weighted-average number of shares outstanding, basic and diluted   16,307,498    1,662,223 

 

35

 

 

Revenue

 

Revenue increased from nil for the nine months ended September 30, 2025 to $4,473 for the nine months ended September 30, 2026. All revenue in the 2026 period was earned during the third quarter following the commencement of RoboShare’s commercial activities and consisted of robot operating and production services and net marketplace commissions.

 

Cost of Revenue and Gross Loss

 

Cost of revenue increased from nil for the nine months ended September 30, 2025 to $14,114 for the nine months ended September 30, 2026. All cost of revenue in the 2026 period consisted of software amortization recognized during the third quarter, following the commencement of amortization in July 2026. We recorded a gross loss of $9,641 for the 2026 period, compared with nil for the corresponding 2025 period, as software amortization exceeded the $4,473 of revenue earned following the commencement of RoboShare’s commercial activities.

 

Expenses

 

General and Administrative Expenses

 

General and administrative expenses increased by $4,918,577, or 85%, from $5,780,572 for the nine months ended September 30, 2025 to $10,699,149 for the nine months ended September 30, 2026. The increase included $2,000,506 of noncash consulting expense recognized in connection with shares of common stock issued to a consultant in September 2026, representing approximately 41% of the increase. The remaining net increase of $2,918,071 related to other general and administrative costs supporting our technology and robotics business activities and public company operations.

 

Sales and Marketing Costs

 

Sales and marketing expenses increased from nil for the nine months ended September 30, 2025 to $743,937 for the nine months ended September 30, 2026. The increase primarily consisted of approximately $712,000 of seminar and other marketing expenses, principally related to marketing activities during the first half of 2026, and $32,000 of advertising expenses.

 

Research and Development Costs

 

Research and development expenses decreased by $146,412, or 94%, from $156,558 for the nine months ended September 30, 2025 to $10,146 for the nine months ended September 30, 2026. The decrease resulted from the cessation of our legacy biotechnology development activities. The 2026 expense consisted of residual chemistry, manufacturing and controls costs for QN-302 incurred during the first half of the year; no research and development expense was incurred during the third quarter.

 

Credit Loss Expense – Short-Term Note Receivable

 

Credit loss expense on short-term notes receivable was $142,574 for the nine months ended September 30, 2026, compared with a net reversal of $99,000 for the nine months ended September 30, 2025. The 2026 expense resulted from an adjustment to the expected credit loss allowance on the Marizyme notes during the first quarter, before those notes were settled and extinguished in May 2026.

 

Other Expense (Income), Net

 

(Gain) Loss on Change in Fair Value of Warrant Liabilities

 

We recognized a gain on change in fair value of warrant liabilities of $67,255 for the nine months ended September 30, 2026, compared with a loss of $93,148 for the nine months ended September 30, 2025. The 2026 gain primarily reflected the decline in our common stock price during the first half of the year, partly offset by a $7,371 fair value loss during the third quarter. Warrant liabilities decreased from $141,878 at December 31, 2025 to $74,623 at September 30, 2026.

 

(Gain) Loss Change in Fair Value of Convertible Debt

 

We recognized a gain on change in fair value of convertible debt of $10,236 for the nine months ended September 30, 2026, compared with a loss of $159,793 for the nine months ended September 30, 2025. The 2026 gain arose before repayment of the remaining convertible debt in January 2026. No further fair value adjustments were recognized after repayment.

 

Loss on Settlement of Short-Term Note Receivable

 

Loss on settlement of short-term notes receivable was $375,844 for the nine months ended September 30, 2026, compared with nil for the nine months ended September 30, 2025. The loss arose from the May 2026 settlement of the Marizyme notes, which had a net carrying amount of $475,844 immediately before settlement, for cash consideration of $100,000.

 

Impairment of Intangible Assets

 

Impairment of intangible assets was $182,619 for the nine months ended September 30, 2026, compared with nil for the nine months ended September 30, 2025. The charge resulted from the write-off of capitalized software costs for discontinued projects during the first quarter of 2026. No additional impairment was recognized during the third quarter.

 

36

 

 

Interest Expense

 

Interest expense decreased from $635,607 for the nine months ended September 30, 2025 to nil for the nine months ended September 30, 2026. The 2025 expense primarily reflected interest and amortization of penalties on promissory notes. Our remaining convertible debt was repaid in January 2026, and no debt for borrowed money was outstanding at September 30, 2026.

 

Interest Income

 

Interest income was $448,135 for the nine months ended September 30, 2026, compared with $449,249 for the nine months ended September 30, 2025. The 2026 amount consisted of approximately $275,358 of interest on the Marizyme notes before their settlement in May 2026, $16,096 of interest on advances to FFAI and $154,489 of dividend income on cash sweep balances. Income from cash sweep balances and FFAI advances offset the reduction in interest income following settlement of the Marizyme notes.

 

Loss on Issuance of Convertible Debt

 

Loss on issuance of convertible debt decreased from $91,943 for the nine months ended September 30, 2025 to nil for the nine months ended September 30, 2026. The 2025 loss arose from the issuance of convertible debt, while no new convertible debt was issued during the 2026 period.

 

Loss on ELOC Facility and ELOC Commitment Fee

 

During the nine months ended September 30, 2026, we recognized a $100,000 ELOC commitment fee and $3,915 of losses on ELOC forward contracts, compared with nil for both items in the corresponding 2025 period. The commitment fee related to our equity purchase facility with GKA. The forward contract losses reflected the difference between the fair value of the shares issued and the contractual net proceeds for the completed purchases, including the effect of draw fees.

 

Net Loss on Digital Assets

 

We recognized a net loss on digital assets of $1,250,556 for the nine months ended September 30, 2026, compared with nil for the nine months ended September 30, 2025. The 2026 loss reflected approximately $3.9 million of realized losses and $2.9 million of unrealized losses, partly offset by approximately $5.6 million of unrealized gains and reversals of previously recognized unrealized losses. The third quarter generated a net gain of $1,679,390 as we substantially liquidated our holdings. We did not hold digital assets during the corresponding 2025 period.

 

37

 

 

Liquidity and Going Concern

 

The Company has incurred recurring operating losses and expects further losses. At September 30, 2026, accumulated deficit was approximately $153.0 million. Net cash used in operating activities for the nine months ended September 30, 2026 was approximately $10.1 million, compared with $7.0 million for the year ended December 31, 2025. At September 30, 2026, cash and cash equivalents were approximately $3.2 million, and remaining digital assets were approximately $2. Substantially all digital assets had been disposed of by quarter end.

 

Current liabilities were approximately $1.9 million at September 30, 2026, comprising $1.3 million of accounts payable, $0.3 million of related-party payables, $0.2 million of accrued expenses and other current liabilities, and $74,623 of warrant liabilities. Operating expenses during the third quarter of 2026 were approximately $4.3 million. No debt for borrowed money was outstanding at quarter end. During the nine months ended September 30, 2026, the Company repaid $132,000 of convertible debt principal.

 

We expect to continue to have net losses and negative cash flow from operations, which will challenge our near-term liquidity. RoboShare began generating revenue during the third quarter of 2026, with revenue of $4,473 and $4,473 for the three and nine months ended September 30, 2026, respectively. These operations remain in the early stages of commercialization and have not generated sufficient recurring operating cash inflows to fund the Company’s operating requirements.

 

Management’s plans to mitigate liquidity constraints include continued operating expense discipline, commercialization of RoboShare, integration and development of the robotics business acquired from FFAI, the Company’s majority stockholder, and pursuit of strategic partnerships and additional equity or debt financing. On October 23, 2026, the Company completed its acquisition of FFAI’s robotics business. Management plans to expand the acquired business through robot sales, deployment and related services that complement RoboShare. The acquisition consideration consisted of equity securities, and the transaction did not provide cash proceeds to fund operations. Successful execution of these plans depends on customer demand, integration, fulfillment capabilities and sufficient operating funding. See Note 19 — Subsequent Events.

 

On October 12, 2026, the Company entered into a securities purchase agreement with certain investors to issue shares of the Company’s common stock (and, to the extent required by a beneficial ownership limitation, Series D non-voting convertible preferred stock) for aggregate gross proceeds of up to $10.0 million in the PIPE. The investors may fund their subscriptions on or before the fifteenth business day following that closing. The PIPE has no minimum aggregate funding condition, the net proceeds are to be used for the development and operations of the Company’s robotics business, and completion of the acquisition is not conditioned on the PIPE or any other financing. As of the date of this Quarterly Report, the acquisition has closed and the Company has received $300,000 under the PIPE from one investor, whose purchase of Series D Preferred Stock will close upon effectiveness of the related certificate of designation. The Company may sell additional securities under the PIPE, but no other investor is currently committed to purchase, and there can be no assurance that any additional amount will be funded. See Note 19 — Subsequent Events.

 

In November 2026, the Company designated 445,236 shares of Series C-1 Non-Voting Convertible Preferred Stock (the “Series C-1 Preferred Stock”), which it expects to issue to Curvature Securities, LLC, its financial advisor for the acquisition, in payment of a transaction fee that became payable on the closing. Each share is convertible into one share of common stock once the required stockholder approval is effective. The fee was contingent on the closing and was not accrued at September 30, 2026.

 

Management also plans to seek additional equity or debt financing, including private placements, public offerings and potential financial support from FFAI, and to utilize the Company’s equity purchase facility with GKA. The facility provides for purchases of up to $50.0 million of common stock, subject to contractual conditions. Actual proceeds depend on market prices, trading volume, available resale registration capacity, applicable ownership and issuance limitations and other contractual requirements. The undrawn commitment does not represent cash available to fund operations. See Note 15 — Stockholders’ Equity and Note 19 — Subsequent Events.

 

As a result, management’s plans are not considered probable of being effectively implemented and do not alleviate the substantial doubt about the Company’s ability to continue as a going concern. Accordingly, the Company’s limited liquidity, recurring operating losses, lack of sufficient recurring operating cash flows and dependence on additional financing collectively raise substantial doubt about its ability to continue as a going concern for the one-year period following the date these condensed consolidated financial statements are issued.

 

The accompanying unaudited condensed consolidated financial statements have been prepared assuming that we will continue as a going concern. They do not include adjustments to the recoverability or classification of assets or the amounts and classification of liabilities that would be necessary if we were unable to continue as a going concern.

 

Contractual Obligations and Commitments

 

We have no material contractual obligations that are not fully recorded on our unaudited condensed consolidated balance sheets or fully disclosed in the notes to the financial statements.

 

38

 

 

Cash Flows

 

The following table sets forth the significant sources and uses of cash for the periods set forth below:

 

   For the nine months ended September 30, 
   2026   2025 
Net cash (used in) provided by:          
Net cash used in operating activities  $(10,104,256)  $(4,828,985)
Net cash provided by (used in) investing activities   6,196,913    (1,809,500)
Net cash (used in) provided by financing activities   (12,222,694)   44,241,044 
Net change in cash and cash equivalents  $(16,130,037)  $37,602,558 

 

Net Cash Used in Operating Activities

 

Net cash used in operating activities increased from $4,828,985 for the nine months ended September 30, 2025 to $10,104,256 for the nine months ended September 30, 2026. The increase reflected cash payments for consulting, salaries and benefits, professional services and other operating costs, together with settlement of previously accrued related-party obligations. Operating cash flows in the 2026 period reflected a net loss of $12,992,755 and a $1,327,278 decrease in related-party payables. These outflows were partly offset by adjustments for non-cash items, including $2,000,506 of common stock issued to a consultant, $1,250,556 of net digital asset losses, a $375,844 loss on settlement of the Marizyme notes, $182,619 of software impairment, $142,574 of credit loss expense and $337,839 of operating expenses settled in digital assets.

 

During the nine months ended September 30, 2025, net cash used in operating activities was $4,828,985, primarily reflecting a net loss of $6,369,407. Operating cash flows were positively affected by noncash adjustments, including $635,607 of amortization of penalties on promissory notes, $325,635 of common stock issued to consultants and fair value losses on convertible debt and warrant liabilities, together with a $1,156,128 decrease in prepaid expenses and other assets. These items were partly offset by accrued interest income of $428,915, decreases in accounts payable and accrued liabilities, and a $99,000 reversal of the allowance for credit losses.

 

Net Cash Provided by/(Used in) Investing Activities

 

Net cash provided by investing activities was $6,196,913 for the nine months ended September 30, 2026, compared with net cash used in investing activities of $1,809,500 for the nine months ended September 30, 2025. The 2026 inflows consisted of $9,000,202 of proceeds from sales of digital assets and $100,000 received from settlement of the Marizyme notes. These inflows were partly offset by $1,850,000 of advances to FFAI, $715,187 of capitalized software expenditures and $338,102 of purchases of digital assets. The change from the 2025 period primarily reflected the liquidation of digital assets during 2026.

 

During the nine months ended September 30, 2025, net cash used in investing activities was $1,809,500 and consisted entirely of advances under short-term notes receivable.

 

Net Cash (Used in)/Provided by Financing Activities

 

Net cash used in financing activities was $12,222,694 for the nine months ended September 30, 2026, compared with net cash provided by financing activities of $44,241,044 for the nine months ended September 30, 2025. The 2026 outflows consisted of $12,000,000 invested in FFAI securities through GKA, $132,000 of convertible debt repayments and payment of the $100,000 ELOC commitment fee, partly offset by $9,306 of cash proceeds from ELOC purchases. The $2,039 ELOC subscription receivable collected after September 30, 2026 is excluded from cash proceeds for the nine-month period.

 

During the nine months ended September 30, 2025, net cash provided by financing activities was $44,241,044, primarily consisting of $41,911,544 of net proceeds from common and preferred stock private placements, $3,295,000 of promissory note proceeds and $200,000 of convertible debt proceeds. These inflows were partly offset by repayments of $1,033,500 of promissory notes and $132,000 of convertible debt. The change between periods reflected substantial private placement proceeds in 2025 and the investment in FFAI securities in 2026.

 

39

 

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and are not required to provide the information otherwise required under this Item.

 

ITEM 4. CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures

 

We maintain disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Disclosure controls and procedures are controls and other procedures designed to ensure that the information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and our principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

 

With the participation of our principal executive officer and principal financial officer, management evaluated the effectiveness of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, as of September 30, 2026. Based on this evaluation, management concluded that our disclosure controls and procedures were not effective at the reasonable assurance level as of that date.

 

Management identified the following material weaknesses:

 

  ● an insufficient number of accounting personnel to adequately segregate duties;
  ● lack of designed and implemented effective Information Technology General Controls (“ITGC”) related to access controls for our financial accounting system; and
  ● absence of formalized documentation of processes and controls that could be evaluated for proper design and implementation.

 

Due to resource constraints, we are currently unable to employ additional personnel to remediate these material weaknesses. We do not expect remediation until we obtain additional funding to strengthen our accounting department.

 

Changes in Internal Control Over Financial Reporting

 

Effective June 20, 2026, Koti Meka resigned as Chief Financial Officer, and effective June 21, 2026, Jie Sheng was appointed as Chief Financial Officer. The composition of the audit committee also changed during the three months ended September 30, 2026, including the appointment of a new chair. Because the Chief Financial Officer and the audit committee have significant roles in the Company’s internal control over financial reporting, these changes are reasonably likely to affect its internal control over financial reporting. These changes did not remediate the material weaknesses described above, which continued to exist as of September 30, 2026.

 

Other than as described above, there were no changes in the Company’s internal control over financial reporting during the quarter ended September 30, 2026 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

 

40

 

 

PART II - OTHER INFORMATION 

 

ITEM 1. LEGAL PROCEEDINGS

 

From time to time, we may be involved in various legal actions, including claims and proceedings arising in the ordinary course of business. We are currently not a party to any legal proceedings, the adverse outcome of which, in management’s opinion, individually or in the aggregate, would have a material adverse effect on our results of operations or financial position, and, to the best of management’s knowledge, no such litigation is currently pending or threatened.

 

Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, negative publicity, reputational harm and other factors.

 

ITEM 1A. RISK FACTORS

 

As a smaller reporting company under Rule 12b-2 of the Exchange Act, we are not required to include risk factors in this Quarterly Report. The Company’s business, reputation, results of operations and financial condition, as well as the price of its stock, can be affected by a number of factors, whether currently known or unknown, including those described in the section titled “Risk Factors” contained in (i) the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as amended and (ii) the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026. When any one or more of these risks materialize, the Company’s business, reputation, results of operations and financial condition, as well as the price of its stock, can be materially and adversely affected.

 

Except as set forth below, there have been no material changes to the risk factors previously disclosed. The following risk factors should be read together with those previously disclosed risk factors. Additional risks and uncertainties not currently known to the Company, or that the Company currently deems immaterial, may also materially and adversely affect its business, financial condition, and results of operations.

 

There is substantial doubt about our ability to continue as a going concern, and if we are unable to obtain additional financing, we may be required to curtail or cease operations.

 

We have incurred recurring operating losses since inception and expect to continue to incur net losses and negative cash flows from operations for the foreseeable future. As of September 30, 2026, we had an accumulated deficit of approximately $153.0 million. Net cash used in operating activities for the nine months ended September 30, 2026 was approximately $10.1 million, compared with approximately $7.0 million for the year ended December 31, 2025. At September 30, 2026, our cash and cash equivalents were approximately $3.2 million, and remaining digital assets were approximately $2. Substantially all digital assets had been disposed of by quarter end.

 

Our current liabilities were approximately $1.9 million at September 30, 2026, comprising $1.3 million of accounts payable, $0.3 million of related-party payables, $0.2 million of accrued expenses and other current liabilities, and $74,623 of warrant liabilities. Operating expenses during the three months ended September 30, 2026 were approximately $4.3 million. No debt for borrowed money was outstanding at quarter end. During the nine months ended September 30, 2026, we repaid $132,000 of convertible debt principal.

 

We expect to continue to have net losses and negative cash flow from operations, which will challenge our near-term liquidity. RoboShare began generating revenue during the third quarter of 2026, with revenue of $4,473 and $4,473 for the three and nine months ended September 30, 2026, respectively. These operations remain in the early stages of commercialization and have not generated sufficient recurring operating cash inflows to fund our operating requirements.

 

We intend to fund our operations through the sale of equity securities, including under our equity line of credit, debt financing, strategic transactions, and/or reductions in operating expenses. Additional financing may not be available when we need it, on acceptable terms, or at all. If we raise capital by issuing equity or convertible securities, our existing stockholders will be diluted, possibly significantly, and the new securities may carry rights senior to our common stock. If we cannot obtain adequate financing, we may have to significantly delay, scale back, or stop our RoboShare operations or other business activities, sell assets, or seek protection under bankruptcy laws. In that case, our stockholders could lose all or part of their investment.

 

Our condensed consolidated financial statements have been prepared assuming we will continue as a going concern. They do not include any adjustments that would be required if we were unable to continue as a going concern, such as adjustments needed to liquidate our assets and discharge our liabilities outside the normal course of business, at amounts that may differ from those reflected in the financial statements. The substantial doubt about our ability to continue as a going concern could also hurt our stock price and our ability to raise capital, enter into commercial arrangements, and retain employees.

 

We are subject to the risks of the robotics business we acquired from FFAI.

 

On October 23, 2026, we acquired the robotics business of FFAI, our majority stockholder. The following risk factors relating to that business are incorporated herein by reference: (i) the risk factors captioned “Our robotics business is subject to significant risks relating to market development, customer demand, supply planning and servicing, and the market for our robotics products and services may not develop as anticipated” and “Regulatory restrictions on foreign-produced advanced robotic devices could materially adversely affect our business, results of operations and growth prospects” in Part II, Item 1A of FFAI’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the SEC on August 13, 2026; and (ii) the risk factor captioned “Changes in U.S. and international trade policies, including the export and import controls and laws, particularly with regard to China, may adversely impact our business and operating results” in Part I, Item 1A of FFAI’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 31, 2026. As used in those risk factors, “we,” “us,” “our” and “our robotics business” refer, for purposes of this Quarterly Report, to the Company and the robotics business it now owns. We also depend on FFAI for transition services and licensed technology, have advanced $2.0 million to FFAI on an unsecured basis, and are controlled by FFAI, whose interests may differ from those of our other stockholders. FFAI has disclosed substantial doubt about its ability to continue as a going concern, and FFAI may be unable to repay the amounts we have advanced or to continue providing services to us. Conversion of the Series C Preferred Stock issued in the acquisition into 65,474,624 shares of common stock will substantially dilute our other stockholders.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

Unregistered Sales of Equity Securities

 

In September 2026, the Company issued 1,144,867 shares of common stock to an advisor as compensation for advisory services. The shares were issued in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended, as a transaction not involving a public offering.

 

Purchases of Equity Securities by the Issuer and Affiliated Purchasers

 

None.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

 

None.

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not applicable.

 

41

 

 

ITEM 5. OTHER INFORMATION

 

Entry into a Material Definitive Agreement

 

SPA Amendment

 

On November 11, 2026, the Company entered into a First Amendment (the “SPA Amendment”) to the Securities Purchase Agreement, dated as of October 12, 2026 (the “SPA”), with a non-U.S. investor (the “Investor”). The SPA was previously disclosed in the Company’s Current Report on Form 8-K filed on October 14, 2026. Under the SPA Amendment:

 

●the Investor will purchase 200,000 shares of the Company’s Series D Non-Voting Convertible Preferred Stock (the “Series D Preferred Stock”) at $1.50 per share, for an aggregate subscription amount of $300,000, and is required to fund on or before November 13, 2026;
●the closing occurs on the date the Certificate of Designation for the Series D Preferred Stock becomes effective;
●the outside date for the closing is extended to November 30, 2026; and
●the resale registration statement for the shares of common stock issuable on conversion of the Series D Preferred Stock will be filed within 45 days after the closing.

 

The Series D Preferred Stock may not be converted into common stock until the Company obtains stockholder approval under Nasdaq Listing Rule 5635, complies with Regulation 14C under the Exchange Act, and the related amendment to its Certificate of Incorporation becomes effective. The Company also agreed to reimburse up to $20,000 of the Investor’s legal fees, subject to the Investor’s funding of its subscription amount.

 

The SPA provides for the sale of up to $10.0 million of the Company’s securities. The Company may seek to sell additional shares of Series D Preferred Stock or other securities to other investors under the SPA or otherwise. Any additional sale would be subject to agreement on definitive terms and, to the extent required, stockholder approval under Nasdaq Listing Rule 5635. There can be no assurance that the Company will obtain any additional funding on acceptable terms or at all.

 

The foregoing description is qualified in its entirety by reference to the form of SPA Amendment, filed as Exhibit 10.1 to this Quarterly Report on Form 10-Q.

 

Second Amendment to Common Shares Purchase Agreement

 

On November 11, 2026, the Company and GKA entered into a Second Amendment to the Common Shares Purchase Agreement, effective June 16, 2026, as previously amended (the “Purchase Agreement”), which governs the Company’s committed equity facility with GKA. The Second Amendment changes the purchase price for each VWAP purchase from 93% of the lowest daily volume weighted average price (“VWAP”) over the purchase date and the two preceding trading days to 100% of the VWAP on the purchase date, replaces the 3% transaction fee retained by GKA with a tiered fee equal to 8%, 5% and 3% of cumulative gross purchase amounts up to $10.0 million, above $10.0 million through $30.0 million, and above $30.0 million, respectively, and entitles GKA to retain its brokerage commissions on resales, capped at 1% of each gross purchase amount.

 

The foregoing description is qualified in its entirety by reference to the Second Amendment, filed as Exhibit 10.2 to this Quarterly Report on Form 10-Q.

 

Letter Agreement with GKA

 

On November 15, 2026, the Company and GKA entered into a letter agreement, effective as of September 14, 2026, confirming the terms on which GKA holds shares of common stock delivered to it in advance of settlement of VWAP purchases under the Purchase Agreement, including the Company’s right to require their return at any time without payment of consideration, GKA’s waiver of voting rights and of any right to dividends or other distributions in respect of such shares, and restrictions on their transfer. The foregoing description is qualified in its entirety by reference to the letter agreement, filed as Exhibit 10.4 to this Quarterly Report on Form 10-Q.

 

Credit Facility Agreement with FFAI

 

On November 10, 2026, the Company entered into a credit facility agreement with FFAI, the Company’s majority stockholder, dated as of November 10, 2026 and effective as of July 20, 2026 (the “Credit Facility Agreement”), which documents the related-party advances to FFAI described in Note 17 to the unaudited condensed consolidated financial statements. The Credit Facility Agreement provides for an uncommitted, non-revolving delayed draw credit facility of up to $2.0 million. The Company has no obligation to make any advance, and each advance requires the prior approval of a special committee of the Board of Directors of the Company composed solely of directors who are independent of, and disinterested with respect to, FFAI. The Company has advanced the full $2.0 million, including a final advance of $150,000 on October 12, 2026, and no further amounts are available under the facility. Advances bear interest at 10% per annum, or 15% per annum following an event of default, are unsecured, rank pari passu with FFAI’s other unsecured and unsubordinated indebtedness, may be prepaid without penalty, and mature on July 20, 2027.

 

The foregoing description is qualified in its entirety by reference to the Credit Facility Agreement, filed as Exhibit 10.3 to this Quarterly Report on Form 10-Q.

 

Termination of a Material Definitive Agreement

 

On November 11, 2026, the Company and the other purchaser under the SPA entered into an agreement terminating the SPA as to that purchaser. The purchaser had not paid any portion of its subscription amount, and no securities were issued to it. The parties released each other from claims arising under the SPA. The Company did not incur any early termination penalties.

 

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On November 13, 2026, Jie Sheng resigned as President of the Company. Mr. Sheng continues to serve as the Company’s Chief Financial Officer and as a member of the Board of Directors. Mr. Sheng’s resignation did not result from any disagreement with the Company on any matter relating to its operations, policies or practices. The Company does not intend to appoint a successor President at this time.

 

Certificates of Designation

 

The Company intends to file with the Secretary of State of the State of Delaware a Certificate of Designation of Preferences, Rights and Limitations of the Series D Preferred Stock (the “Series D Certificate of Designation”), which will designate 200,000 shares of the Company’s preferred stock as Series D Preferred Stock and will become effective upon filing. The terms of the Series D Preferred Stock will be:

 

●Stated value: $1.50 per share.
●Conversion: each share is convertible into one share of common stock, subject to customary adjustments.
●Voting: no voting rights, except as required by the Delaware General Corporation Law.
●Stockholder approval blocker: no share of Series D Preferred Stock may be converted, and no related voting rights may be exercised, until the Company has obtained the requisite stockholder approval, 20 calendar days have passed after the definitive information statement on Schedule 14C is mailed to stockholders, and any required amendment to the Certificate of Incorporation has become effective.
●Beneficial ownership limit: conversion is limited so that the holder does not beneficially own more than 4.99% of the outstanding common stock. The holder may raise the limit to up to 9.99% on 61 days’ notice.

 

The foregoing description is qualified in its entirety by reference to the form of Series D Certificate of Designation, filed as Exhibit 3.1 to this Quarterly Report on Form 10-Q.

 

Certificate of Designation of Series C-1 Preferred Stock

 

The Company intends to file with the Secretary of State of the State of Delaware a Certificate of Designation designating 445,236 shares of its preferred stock as Series C-1 Non-Voting Convertible Preferred Stock, effective on filing, and to issue those shares to pay the transaction fee owed to Curvature Securities, LLC, its financial advisor for the acquisition of FFAI’s robotics business. Each share will have a stated value of $2.246 and will be convertible into one share of common stock, subject to adjustment for stock splits and similar events, but only after the stockholder approval required by the Nasdaq listing rules has become effective. The Series C-1 Preferred Stock will have no voting rights except as required by Delaware law, will share in dividends and liquidating distributions with the common stock on an as-converted basis, and will not be redeemable.

 

This description is qualified by the form of Certificate of Designation, filed as Exhibit 3.2 to this report.

 

Section 204 Notice

 

On November 12, 2026, the Board ratified under Section 204 of the Delaware General Corporation Law the issuance of 60,257 shares of common stock on or about September 29, 2025, which had not been approved by the Board as required by Sections 152, 153 and 157 of the Delaware General Corporation Law. Any claim that the ratified issuance is void or voidable due to the failure of authorization, or that the Court of Chancery should declare in its discretion that the ratification not be effective or be effective only on certain conditions, must be brought within 120 days from the later of the validation effective time and the date of this notice.

 

Rule 10b5-1 Trading Arrangement

 

During the three months ended September 30, 2026, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.

 

ITEM 6. EXHIBITS

 

Exhibit No.   Description
3.1*  

Form of Certificate of Designation of Preferences, Rights and Limitations of Series D Non-Voting Convertible Preferred Stock.

3.2*   Form of Certificate of Designation of Preferences, Rights and Limitations of Series C-1 Non-Voting Convertible Preferred Stock.
3.3  

Certificate of Amendment to the Amended and Restated Certificate of Incorporation of AIxCrypto Holdings, Inc., filed with the Secretary of State of the State of Delaware on September 29, 2026 (effective September 30, 2026) (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the SEC on September 29, 2026).

3.4   Amended and Restated Bylaws of FF EAI Robotics Ecosystem Inc., as amended through September 30, 2026 (incorporated by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K filed with the SEC on September 29, 2026).
10.1*†   Form of First Amendment to Securities Purchase Agreement, dated November [11], 2026
10.2*   Second Amendment to Common Shares Purchase Agreement, dated as of November 11, 2026, by and between FF EAI Robotics Ecosystem Inc. and Gold King Arthur Holding Limited.
10.3*   Credit Facility Agreement, dated as of November 10, 2026 and effective as of July 20, 2026, between FF EAI Robotics Ecosystem Inc. and Faraday Future Intelligent Electric Inc.
10.4*   Letter Agreement, dated as of November 15, 2026, between FF EAI Robotics Ecosystem Inc. and Gold King Arthur Holding Limited
10.5   Consulting Agreement, dated July 29, 2026, between AIxCrypto Holdings, Inc. and Aibot US Operation Inc. (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on July 31, 2026).
31.1*   Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as amended.
31.2*   Certification of Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as amended.
32.1**   Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2**   Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS*   Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH*   Inline XBRL Taxonomy Extension Schema Document.
101.CAL*   Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF*   Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB*   Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE*   Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104*   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

 

* Filed herewith.

** Furnished herewith.

† Certain schedules and annexes have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company will furnish a copy of any omitted schedule or annex to the SEC upon request.

 

42

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

November 16, 2026 FF EAI Robotics Ecosystem Inc.
     
  By: /s/ Yueting Jia
  Name Yueting Jia
  Title: Chief Executive Officer (Principal Executive Officer)

 

  By: /s/ Jie Sheng
  Name Jie Sheng
  Title: Chief Financial Officer (Principal Financial and Accounting Officer)

 

43

Keep reading